[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 761
1. Miralles Alonso F, Ortega González LM, Oropesa González L, Francisco RD, de Paz VC: [Behaviour of HIV/AIDS-related lymphoma in Pedro Kouri Institute. 2004-2005]. Rev Cubana Med Trop; 2006 Sep-Dec;58(3):248-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Behaviour of HIV/AIDS-related lymphoma in Pedro Kouri Institute. 2004-2005].
  • [Transliterated title] Comportamiento de linfoma relacionado con VIH/SIDA en el Instituto "Pedro Kourí". 2004-2005.
  • A prospective and descriptive study of 20 patients infected with HIV and admitted to "Pedro Kouri" Institute of Tropical Disease after a diagnosis of lymphoma was conducted.
  • They were all evaluated at the onset of diagnosis by a thorough medical record exam and supportive studies such as complete blood count, globular sedimentation speed, CD4+ count, lactic acid dehydrogenase, HIV viral load, cytology and biopsy.
  • It called our attention that high levels of lactic acid dehydrogenase and extrapulmonary location of tumors were related.
  • Statistically significant association was found (p < 0.05) between immunosuppresion condition of the patients given by CD4+ count below 350 cell/mm3 and advanced staging of the tumoral disease (stages III and IV).
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23424794.001).
  • [ISSN] 0375-0760
  • [Journal-full-title] Revista cubana de medicina tropical
  • [ISO-abbreviation] Rev Cubana Med Trop
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Cuba
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


2. Newton R, Carpenter L, Casabonne D, Beral V, Babiker A, Darbyshire J, Weller I, Weiss R, Kwan A, Bourboulia D, Munoz F, Lagos D, Boshoff C: A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1. Br J Cancer; 2006 May 22;94(10):1504-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.
  • Antibody titres against Kaposi's sarcoma associated herpesvirus (KSHV or human herpesvirus 8 (HHV-8)) and Epstein-Barr virus (EBV) were examined in people who subsequently developed Kaposi's sarcoma and non-Hodgkin's lymphoma, within randomised controlled trials of antiretroviral therapy in adults infected with the human immunodeficiency virus-1 (HIV).
  • For each case of Kaposi's sarcoma (n=189) and each case of non-Hodgkin's lymphoma (n=67), which developed after randomisation, one control was randomly selected from other trial participants, after matching for age, sex, ethnicity, mode of HIV transmission, type of treatment received and period of follow-up.
  • Virtually, all cases and controls had anti-EBV antibodies detected and the OR for non-Hodgkin's lymphoma associated with a doubling of the anti-EBV antibody titre was estimated to increase by a multiplicative factor of 1.3 (95% CI 0.9-1.7, P=0.1).
  • Kaposi's sarcoma was not associated with antibody levels against EBV (P=0.4) and non-Hodgkin's lymphoma was not associated with antibodies against KSHV (latent P=0.3; lytic P=0.5).
  • In conclusion, among human immunodeficiency virus infected people, high levels of antibodies against KSHV latent and lytic antigens are strongly associated with subsequent risk of Kaposi's sarcoma but not non-Hodgkin's lymphoma.
  • Antibody titre to EBV does not appear to be strongly associated with subsequent risk of Kaposi's sarcoma or non-Hodgkin's lymphoma in HIV infected people.
  • [MeSH-major] Antibodies, Viral / blood. HIV Infections / virology. HIV-1. Herpesvirus 4, Human / immunology. Herpesvirus 8, Human / immunology. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / virology
  • [MeSH-minor] Adult. Female. HIV Seronegativity. Humans. Male. Nuclear Proteins / immunology. Phosphoproteins / immunology. Prospective Studies. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2004 Feb 20;18(3):485-93 [15090801.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1468-74 [10469747.001]
  • [Cites] AIDS. 1996 Jul;10(8):867-80 [8828744.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):1-6 [9709294.001]
  • [Cites] Cancer Causes Control. 1993 May;4(3):187-93 [8391336.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):226-32 [12455037.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):502-4 [12888820.001]
  • [Cites] Int J Cancer. 1991 Sep 30;49(3):387-93 [1655660.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):1-5 [10360811.001]
  • [Cites] J Clin Microbiol. 2002 Feb;40(2):325-9 [11825937.001]
  • [Cites] J Virol. 1967 Oct;1(5):1045-51 [4912237.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):233-40 [12455038.001]
  • [Cites] Lancet. 1994 Apr 9;343(8902):871-81 [7908356.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):194-202 [11158187.001]
  • [Cites] Infect Agent Cancer. 2006 Sep 14;1:2 [17150131.001]
  • [Cites] AIDS. 1998 Dec 24;12(18):2481-8 [9875587.001]
  • [Cites] Lancet. 1996 Aug 3;348(9023):283-91 [8709686.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1940-9 [10837173.001]
  • (PMID = 16705315.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0800168; United Kingdom / Medical Research Council / / G8712499
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / latent nuclear antigen (LNA)
  • [Other-IDs] NLM/ PMC2361279
  •  go-up   go-down


3. Engels EA, Pfeiffer RM, Landgren O, Moore RD: Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr; 2010 May 1;54(1):78-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era.
  • HIV-infected persons treated with highly active antiretroviral therapy (HAART) continue to have elevated risk for non-Hodgkin lymphoma (NHL).
  • We conducted a retrospective cohort study of NHL among patients at an urban HIV clinic (N = 3025).
  • NHL risk increased with declining CD4 count (P trend < 0.0001) and increasing HIV viral load (P trend = 0.005).
  • In a multivariable model, NHL risk was independently associated with both current CD4 count (hazard ratios 7.7 and 3.8, respectively, for CD4 counts 0-99 and 100-249 vs. 250+ cells/mm(3); P trend < 0.0001) and prior time spent with a viral load above 5.00 log(10) copies/mL (hazard ratios of 3.4, 2.6, and 6.8, respectively, for 0.1-0.4, 0.5-1.4, and 1.5+ yr vs. 0 yr; P trend = 0.004).
  • Among HIV-infected individuals in the HAART era, NHLs are linked to immunosuppression and extended periods of uncontrolled HIV viremia.
  • The association with high-level viremia could reflect detrimental effects on immune function related to incompletely effective HAART or direct effects on B cells.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr HIV Res. 2004 Jan;2(1):11-21 [15053337.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1548-63 [15470219.001]
  • [Cites] N Engl J Med. 1983 Aug 25;309(8):453-8 [6224088.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Eur J Haematol. 1995 Oct;55(4):245-50 [7589342.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17 Suppl 1:S38-41 [9586651.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):256-64 [10454946.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):444-8 [16894291.001]
  • [Cites] Ann Rheum Dis. 2007 Jan;66(1):23-7 [16569685.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2349-50 [17551128.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Allergy Clin Immunol. 2008 Jul;122(1):12-9; quiz 20-1 [18547629.001]
  • [Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Am J Epidemiol. 2000 Nov 15;152(10):923-33 [11092434.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] AIDS. 2004 Mar 5;18(4):673-81 [15090773.001]
  • (PMID = 20418723.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA016893; United States / NIDA NIH HHS / DA / R01 DA011602; United States / NIDA NIH HHS / DA / K24 DA000432; United States / NIDA NIH HHS / DA / K24 DA000432-10; United States / NIDA NIH HHS / DA / DA011602-13; United States / NIAID NIH HHS / AI / U01 AI069918-05; United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NIDA NIH HHS / DA / R01 DA11602; United States / NIAID NIH HHS / AI / U01 AI069918; United States / NIAAA NIH HHS / AA / R01 AA016893-01A2; United States / NIDA NIH HHS / DA / K24 DA00432; United States / NIDA NIH HHS / DA / R01 DA011602-13; United States / NIAAA NIH HHS / AA / R01 AA16893; United States / Intramural NIH HHS / / Z01 CP010150-09; United States / NIAID NIH HHS / AI / AI069918-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS152223; NLM/ PMC3078556
  •  go-up   go-down


Advertisement
4. Gujral S, Shet TM, Kane SV: Morphological spectrum of AIDS-related plasmablastic lymphomas. Indian J Pathol Microbiol; 2008 Jan-Mar;51(1):121-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological spectrum of AIDS-related plasmablastic lymphomas.
  • We have had a recent spurt in cases of AIDS-related lymphoma (ARL) at our centre.
  • Most of these cases are aggressive mature B cell lymphomas, mainly plasmablastic lymphoma (PBL) and diffuse large B-cell lymphoma (DLBCL).
  • Diagnosis was based on morphology, immunohistochemistry, proliferation index, HIV positive status and its preference to extranodal sites (mostly mucosa based).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunoglobulin Light Chains / analysis. Leukemia, Plasma Cell / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Syndecan-1 / analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417882.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Light Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


5. Stone VE, Bounds BC, Muse VV, Ferry JA: Case records of the Massachusetts General Hospital. Case 29-2009. An 81-year-old man with weight loss, odynophagia, and failure to thrive. N Engl J Med; 2009 Sep 17;361(12):1189-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Liver / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. Aged, 80 and over. Candidiasis, Oral / diagnosis. Candidiasis, Oral / etiology. Deglutition Disorders / etiology. Diabetes Mellitus, Type 2 / complications. Diagnosis, Differential. Failure to Thrive / etiology. Fatal Outcome. Humans. Lung / pathology. Lung / radiography. Male. Tomography, X-Ray Computed. Weight Loss

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19759382.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Jiang Y, Xu D, Zhao Y, Zhang L: Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS One; 2008 Feb 06;3(2):e1569
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma.
  • BACKGROUND: Both Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are members of the human gamma herpesvirus family: each is associated with various human cancers.
  • The majority of AIDS-associated primary effusion lymphoma (PEL) are co-infected with both KSHV and EBV.
  • Our data about putative interactions between EBV and KSHV would be applicable to the majority of AIDS-associated PELs and may be relevant to the pathogenesis of PELs.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2003 Jun 5;310(2):199-206 [12781707.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Gen Virol. 2003 Aug;84(Pt 8):1941-9 [12867624.001]
  • [Cites] J Virol. 2003 Aug;77(16):8893-914 [12885907.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jun;82(12):4085-9 [2987963.001]
  • [Cites] EMBO J. 1986 Dec 1;5(12):3243-9 [3028777.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1652-6 [2830625.001]
  • [Cites] EMBO J. 1989 May;8(5):1447-53 [2548844.001]
  • [Cites] EMBO J. 1989 Jun;8(6):1819-26 [2548857.001]
  • [Cites] J Virol. 1990 Jan;64(1):313-21 [2152819.001]
  • [Cites] J Virol. 1990 Mar;64(3):1143-55 [2154599.001]
  • [Cites] J Virol. 1990 Mar;64(3):1227-32 [2154606.001]
  • [Cites] J Virol. 1990 Jun;64(6):2560-8 [2159531.001]
  • [Cites] J Virol. 1990 Aug;64(8):3753-9 [2164595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(23):9459-63 [2174563.001]
  • [Cites] J Virol. 2007 Jun;81(11):5788-806 [17392367.001]
  • [Cites] J Virol. 2007 Sep;81(17):9279-91 [17596302.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 [10591086.001]
  • [Cites] J Virol. 1993 Dec;67(12):7648-53 [8230484.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1929-38 [8114724.001]
  • [Cites] J Virol. 1994 May;68(5):3354-63 [8151794.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2748-59 [8654372.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] Infect Agents Dis. 1996 Oct;5(4):215-22 [8884366.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):31799-802 [8943219.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] J Virol. 2000 Feb;74(3):1061-8 [10627515.001]
  • [Cites] J Virol. 2000 Mar;74(6):2550-7 [10684269.001]
  • [Cites] Oncogene. 1991 Feb;6(2):195-204 [1847997.001]
  • [Cites] Genes Dev. 1991 Dec;5(12B):2441-54 [1661258.001]
  • [Cites] J Virol. 1992 Aug;66(8):5030-9 [1321285.001]
  • [Cites] J Virol. 1993 Aug;67(8):4651-8 [8392605.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1617-26 [10022850.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3216-23 [10082588.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Aug;73(8):6551-8 [10400751.001]
  • [Cites] J Virol. 1999 Sep;73(9):7271-7 [10438815.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Virol. 2005 Apr;79(8):4651-63 [15795251.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Jul;79(13):8493-505 [15956592.001]
  • [Cites] J Virol. 2005 Nov;79(21):13298-309 [16227252.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] J Virol. 2000 Dec;74(24):11800-10 [11090180.001]
  • [Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]
  • [Cites] J Virol. 2001 Jan;75(1):341-50 [11119603.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(5):2388-99 [11160742.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Virol. 2001 Oct;75(19):9446-57 [11533207.001]
  • [Cites] J Virol. 2001 Oct;75(19):9509-16 [11533213.001]
  • [Cites] J Virol. 2001 Nov;75(21):10334-47 [11581402.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] J Virol. 2001 Dec;75(24):12393-401 [11711629.001]
  • [Cites] J Virol. 2002 Feb;76(3):998-1003 [11773375.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6438-42 [11741976.001]
  • [Cites] Nat Med. 2002 Jun;8(6):594-9 [12042810.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Virology. 2002 Aug 1;299(2):301-14 [12202233.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] J Virol. 2003 Mar;77(6):3809-15 [12610155.001]
  • (PMID = 18253508.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108951; United States / NCRR NIH HHS / RR / RR15635; United States / NIAID NIH HHS / AI / R21 AI059132; United States / NCRR NIH HHS / RR / P20 RR015635; United States / NCI NIH HHS / CA / CA108951; United States / NIAID NIH HHS / AI / AI59132
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2215330
  •  go-up   go-down


7. Huhn GD, Badri S, Vibhakar S, Tverdek F, Crank C, Lubelchek R, Max B, Simon D, Sha B, Adeyemi O, Herrera P, Tenorio A, Kessler H, Barker D: Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution. AIDS Res Ther; 2010;7:44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution.
  • BACKGROUND: In the HAART era, the incidence of HIV-associated non-Hodgkin lymphoma (NHL) is decreasing.
  • We describe cases of NHL among patients with multi-class antiretroviral resistance diagnosed rapidly after initiating newer-class antiretrovirals, and examine the immunologic and virologic factors associated with potential IRIS-mediated NHL.
  • METHODS: During December 2006 to January 2008, eligible HIV-infected patients from two affiliated clinics accessed Expanded Access Program antiretrovirals of raltegravir, etravirine, and/or maraviroc with optimized background.
  • HIV-related NHL can occur in the setting of immune reconstitution.
  • Potential immunologic, virologic, and newer-class antiretroviral-specific factors associated with rapid development of NHL warrants further investigation.


8. Hongsakul K, Laothamatas J: Computer tomographic findings of the brain in HIV-patients at Ramathibodi Hospital. J Med Assoc Thai; 2008 Jun;91(6):895-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer tomographic findings of the brain in HIV-patients at Ramathibodi Hospital.
  • OBJECTIVE: To determine the underlying cause of the brain lesions in adult HIV patients referred for CT scan at Ramathibodi Hospital and to evaluate accuracy of CT for the diagnosis of the brain lesion.
  • MATERIAL AND METHOD: Data from first CT scan of the brain of 195 adult HIV patients at Ramathibodi Hospital were reviewed The final diagnoses from medical records were assessed followed by CSF analysis, pathological report, and therapeutic treatment.
  • RESULTS: One hundred ninety five adult seropositive patients for HIV underwent CT scan of the brain, 59% were HIV encephalopathy (HIVE), 22% toxoplasmosis, 9% cryptococcoma, 5% tuberculous meningitis, 4% tuberculoma, 3% progressive multifocal leukoencephalopathy (PML), 2% lymphoma, and 1% normal.
  • CONCLUSION: HIV encephalopathy was the most common finding of adult HIV brains.
  • Toxoplasmosis was the most common opportunistic parenchymal brain lesion in adult HIV brains.
  • CT was the modality of choice for diagnosis and exclusion of toxoplasmosis, but it cannot determine the cause of disease showing meningitis pattern.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Brain / physiopathology. Brain Diseases / diagnosis. HIV Infections / complications. Tomography, X-Ray Computed / instrumentation


9. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, Ness A, Reynolds S, Johnson JL, Subbiah V, Bako J, Wabinga H, Abdallah FK, Meyerson HJ, Whalen CC, Lederman MM, Black J, Ayers LW, Katongole-Mbidde E, Remick SC: Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol; 2009 Jul 20;27(21):3480-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
  • PURPOSE Africa is burdened by the AIDS epidemic and attendant increase in HIV/AIDS-related malignancies.
  • Dose-modified oral chemotherapy for AIDS-related non-Hodgkin's lymphoma is one such approach.
  • PATIENTS AND METHODS The oral regimen consisted of lomustine 50 mg/m(2) on day 1 (cycle 1 only), etoposide 100 mg/m(2) on days 1 to 3, and cyclophosphamide/procarbazine 50 mg/m(2) each on days 22 to 26 at 6-week intervals (one cycle) for two total cycles in HIV-infected patients with biopsy-proven non-Hodgkin's lymphoma.
  • The majority of patients were female (59%) and had a poor performance status (63%); 69% of patients had advanced-stage disease; and 18 patients (37%) had access to antiretroviral therapy.
  • The regimen was well tolerated, had modest effects (decline) on CD4(+) lymphocyte counts (P = .077), and had negligible effects on HIV-1 viral replication.
  • Four febrile neutropenia episodes and three treatment-related deaths (6% mortality rate) occurred.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV-1 / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Africa South of the Sahara. Antiretroviral Therapy, Highly Active / trends. CD4 Lymphocyte Count. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. HIV Infections / complications. HIV Infections / drug therapy. Hematopoietic Stem Cell Transplantation. Humans. Kenya. Lomustine / therapeutic use. Male. Middle Aged. Procarbazine / therapeutic use. Treatment Outcome. Uganda. Virus Replication / drug effects. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):532-40 [14595710.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] Am J Med. 1986 Jan;80(1):119-22 [3942143.001]
  • [Cites] Ann Intern Med. 1989 Jun 1;110(11):937-40 [2719427.001]
  • [Cites] Rev Infect Dis. 1989 Nov-Dec;11(6):954-63 [2690289.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3(4):430-7 [2313564.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] Blood. 1993 May 15;81(10):2810-5 [8490187.001]
  • [Cites] Drugs. 1999;58 Suppl 3:99-107 [10711848.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Ann N Y Acad Sci. 2000 Nov;918:362-6 [11131726.001]
  • [Cites] Am J Hematol. 2001 Mar;66(3):178-88 [11279624.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] Biometrics. 1999 Jun;55(2):625-9 [11318225.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] J Am Coll Nutr. 2001 Dec;20(6):609-15 [11771676.001]
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):718-32 [12011222.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1691-702 [8355036.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leuk Lymphoma. 1994 Jul;14(3-4):263-71 [7950915.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):3026-35 [8918501.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] AIDS. 1998;12 Suppl 1:S3-14 [9677185.001]
  • [Cites] Haematologica. 1998 Jun;83(6):508-13 [9676023.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3601-6 [9817281.001]
  • [Cites] Pediatr Blood Cancer. 2005 Mar;44(3):245-50 [15547922.001]
  • [Cites] Cancer Detect Prev. 2005;29(2):133-45 [15829373.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S155-60 [16619692.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):479-86 [16894296.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1141-53 [16971720.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):319 [18380064.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):398-403 [18385682.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19470940.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / TW00011; United States / NCI NIH HHS / CA / R01 CA083528; United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA83528; United States / NCI NIH HHS / CA / U01 CA070081; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA066531; United States / NCI NIH HHS / CA / CA43703; United States / FIC NIH HHS / TW / D43 TW000011; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / U01 CA066531; United States / NIAID NIH HHS / AI / P30 AI036219
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2717754
  •  go-up   go-down


10. Carron PN, Cavassini M, Maeder P, Hugli OW: An unusual cerebral computed tomography image. CJEM; 2010 May;12(3):223, 227-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] AIDS-Related Opportunistic Infections / radiography. Brain Edema / radiography. Consciousness Disorders / radiography. Tomography, X-Ray Computed. Toxoplasmosis, Cerebral / radiography
  • [MeSH-minor] Adult. Brain Neoplasms / diagnosis. Brain Neoplasms / radiography. Diagnosis, Differential. Equatorial Guinea / ethnology. Glioblastoma / diagnosis. Glioblastoma / radiography. Humans. Lymphoma / diagnosis. Lymphoma / radiography. Male. Neurosyphilis / diagnosis. Neurosyphilis / radiography. Prisoners. Switzerland

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522288.001).
  • [ISSN] 1481-8035
  • [Journal-full-title] CJEM
  • [ISO-abbreviation] CJEM
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


11. Sabin CA: HIV viremia and the development of AIDS-related lymphoma in patients treated with highly active antiretroviral therapy. J Infect Dis; 2009 Jul 1;200(1):8-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV viremia and the development of AIDS-related lymphoma in patients treated with highly active antiretroviral therapy.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. HIV Infections / drug therapy. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Anti-HIV Agents / adverse effects. Anti-HIV Agents / therapeutic use. Humans


12. Moore Dalal K, Antonescu CR, Dematteo RP, Maki RG: EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases. Sarcoma; 2008;2008:859407
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases.
  • Background. Epstein-Barr virus (EBV)-related smooth muscle neoplasms (SMNs) have been associated with immune dysregulation, most notably in patients who have undergone solid organ transplantation or in patients with HIV/AIDS.
  • Objective. to report our experience with EBV-related neoplasms as well as describing the first EBV-related SMN in the setting of administration of glucocorticoids and the tumor necrosis factor inhibitor etanercept.
  • Patients are with dysregulated immunity after solid organ transplantation, HIV/AIDS, or with psoriasis after treatment with etanercept.
  • Surgical resection or chemotherapy was successful in delaying progression of disease. Limitations.
  • Conclusion. EBV-related SMNs have variable aggressiveness.
  • While chemotherapy may slow disease progression, resection and improving the host immune status provide the best opportunity for primary tumor control.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1497-505 [15923311.001]
  • [Cites] Transplant Proc. 2005 May;37(4):1839-44 [15919482.001]
  • [Cites] Clin Infect Dis. 2005 May 15;40(10):1521-8 [15844077.001]
  • [Cites] Ann Rheum Dis. 2005 May;64(5):699-703 [15695534.001]
  • [Cites] Leuk Lymphoma. 1997 Oct;27(3-4):303-14 [9402327.001]
  • [Cites] J Med Virol. 1999 Jan;57(1):36-46 [9890420.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):473-83 [18342658.001]
  • [Cites] Arch Pathol Lab Med. 1997 Aug;121(8):834-8 [9278611.001]
  • [Cites] Immunol Rev. 1997 Jun;157:195-216 [9255631.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):204-10 [9217031.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):12-8 [7990860.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):19-25 [7990861.001]
  • [Cites] Crit Rev Oncog. 1989;1(1):27-52 [2488123.001]
  • [Cites] Pediatr Radiol. 1993;23(5):413-4 [8233708.001]
  • [Cites] Nature. 1980 Sep 11;287(5778):164-5 [6253791.001]
  • [Cites] Can Med Assoc J. 1970 Dec 19;103(13):1362-5 [4923839.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):387-91 [15143769.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1531-7 [11886519.001]
  • [Cites] Pediatr Transplant. 2001 Oct;5(5):365-9 [11560757.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):614-21 [10757411.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):473-6 [10199478.001]
  • [Cites] Arthritis Rheum. 2007 Jun 15;57(5):762-7 [17530675.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):75-82 [16330945.001]
  • (PMID = 19079588.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2590677
  •  go-up   go-down


13. Mani D, Dorer RK, Aboulafia DM: Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma; 2009 Aug;9(4):316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukemia following HIV-associated lymphoma.
  • In the highly active antiretroviral therapy era, an increasingly large number of HIV-infected patients are developing non- AIDS-defining cancers (NADCs).
  • As patients survive longer, long-term therapy-related complications take on greater importance.
  • Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
  • With the diagnosis of therapy-related acute myeloid leukemia (AML) secured, he began induction chemotherapy with idarubicin and cytarabine.
  • Through a literature search, we were able to identify 4 additional cases of therapy-related AML in AIDS patients following chemotherapy for lymphomas.
  • The median age of these patients at the time of AML diagnosis was 39 years (range, 33-59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11-48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2-16 weeks).
  • With many HIV-infected patients surviving alkylator and topoisomerase inhibitor-based treatment and radiation therapy for AIDS-defining cancers and NADCs, long-term follow-up for therapy-related complications assumes greater importance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717383.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


14. Breen EC, Epeldegui M, Boscardin WJ, Widney DP, Detels R, Martínez-Maza O: Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin's B-cell lymphoma. AIDS; 2005 Oct 14;19(15):1711-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin's B-cell lymphoma.
  • [MeSH-major] Antigens, CD44 / blood. Biomarkers, Tumor / blood. Lymphoma, AIDS-Related / immunology. Lymphoma, B-Cell / immunology
  • [MeSH-minor] HIV Infections / immunology. Homosexuality. Humans. Male

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] AIDS. 2000 Jul 7;14(10):1460-1 [10930167.001]
  • (PMID = 16184051.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888; United States / NIAID NIH HHS / AI / U01-AI-35039; United States / NIAID NIH HHS / AI / U01-AI-35041; United States / NIAID NIH HHS / AI / U01-AI-35042; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NIAID NIH HHS / AI / U01-AI-37613; United States / NIAID NIH HHS / AI / U01-AI-37984; United States / NIAID NIH HHS / AI / U01-AI35040
  • [Publication-type] Comment; Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Fan H, Kim SC, Chima CO, Israel BF, Lawless KM, Eagan PA, Elmore S, Moore DT, Schichman SA, Swinnen LJ, Gulley ML: Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol; 2005 Jan;75(1):59-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr viral load as a marker of lymphoma in AIDS patients.
  • Epstein-Barr virus (EBV) is implicated in the pathogenesis of acquired immunodeficiency syndrome (AIDS) lymphoma, and viral DNA is present within the malignant cells in about half of affected patients.
  • We examined the extent to which EBV viral load is elevated in the plasma of AIDS lymphoma patients compared to AIDS patients with opportunistic infections.
  • Sixty-one AIDS patients were studied including 35 with lymphoma (24 non-Hodgkin, six Hodgkin, and five brain lymphoma) and 26 with various opportunistic infections.
  • In situ hybridization revealed EBV encoded RNA (EBER) expression in the malignant cells of 17/28 AIDS lymphomas (61%).
  • In 232 serial plasma samples from 35 lymphoma patients and in 128 samples from AIDS controls, EBV viral load was assayed by quantitative-polymerase chain reaction (Q-PCR) using a TaqMan probe targeting the BamH1W sequence.
  • EBV was detected in plasma from all 17 EBER-positive AIDS lymphoma patients, with viral loads ranging from 34 to 1,500,000 copies per ml (median 3,210).
  • Viral load usually fell rapidly upon initiation of lymphoma therapy and remained undetectable except in two patients with persistent tumor.
  • In 11 AIDS patients, whose lymphoma lacked EBER expression, and in 26 control patients without lymphoma, levels of EBV in plasma were usually low or undetectable (range 0-1,995 and 0-2,409, median 0 and 0, respectively).
  • There was no association between EBV viral load and human immunodeficiency virus (HIV) load or CD4 count.
  • In conclusion, EBV viral load shows promise as a tool to assist in diagnosis and management of EBV-related lymphoma patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. DNA, Viral / blood. Epstein-Barr Virus Infections / diagnosis. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Biomarkers / blood. CD4 Lymphocyte Count. Gene Expression / genetics. HIV / isolation & purification. Humans. In Situ Hybridization. Polymerase Chain Reaction. RNA, Viral / analysis. Viral Load

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15543571.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


16. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr, AIDS Associated Malignancies Clinical Trials Consortium: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma; 2006 Mar;6(5):399-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
  • PURPOSE: A consistent association with Epstein-Barr Virus (EBV) distinguishes acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) from that which occurs in the general population.
  • Recent descriptions of long-term remissions in patients with posttransplantation EBV-associated PCNSL who received EBV-specific therapy suggest some antitumor effect is anti-EBV mediated.
  • PATIENTS AND METHODS: We enrolled 4 patients with AIDS-related PCNSL into a novel antiviral and immunomodulatory protocol.
  • All 6 patients had advanced-stage AIDS as reflected by a CD4+ T-lymphocyte cell count of < 50/microL and a detectable human immunodeficiency virus (HIV)-1 viral RNA load (median copies, 135,000/mL; range, 2170-360,000/mL).
  • CONCLUSION: We conclude that for patients with AIDS and PCNSL, treatments with dual efficacy against HIV and EBV merit further investigation.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Interleukins / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality


17. Gucalp A, Noy A: Spectrum of HIV lymphoma 2009. Curr Opin Hematol; 2010 Jul;17(4):362-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of HIV lymphoma 2009.
  • PURPOSE OF REVIEW: HIV-infected individuals remain at an increased risk for developing malignancies despite the use of combined antiretroviral therapy.
  • Lymphomas comprise a large proportion of the malignancies that affect the HIV-infected population in developed countries.
  • This review summarizes the recent progress made in HIV lymphoma research published in 2009 through January 2010.
  • RECENT FINDINGS: The majority of investigation in this field has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising.
  • Rituximab likely improves complete response and possibly overall survival, but may be associated with increased infections in a subset of patients with very low CD4 cell counts.
  • Risk factors associated with the development of lymphoma include low CD4 cell count and likely cumulative HIV viremia.
  • SUMMARY: Overall, the outcome for HIV lymphoma continues to improve as insights into the pathophysiology and treatment advance.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. HIV Infections / therapy. Lymphoma, AIDS-Related / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. CD4 Lymphocyte Count. Combined Modality Therapy. HIV / drug effects. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / therapy. Rituximab

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442655.001).
  • [ISSN] 1531-7048
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 36
  •  go-up   go-down


18. Djunic I, Jevtovic DL, Ranin J, Salemovic D, Tomin D, Mihaljevic B: Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma. Biomed Pharmacother; 2008 Jan;62(1):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
  • BACKGROUND: The majority of patients with AIDS-related non-Hodgkin's lymphoma (ARL) present with advanced disease, aggressive histological type, B-symptoms, and often with an extranodal localization.
  • Twenty-six patients had an aggressive type of lymphoma while 2 had an indolent type.
  • RESULTS: This study demonstrated that significant factors for OS in patients with ARL were the high International Prognostic Index (P=0.019), previous AIDS event (P=0.04), aggressive histological type of NHL (P=0.007) and extranodal disease (P=0.04).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Vincristine / administration & dosage. Yugoslavia

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629445.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


19. Ridha E, Cookson H, Devitt E, Nelson M: Febrile neutropenia in a HIV positive individual post-chemotherapy. J Clin Virol; 2010 May;48(1):2-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Febrile neutropenia in a HIV positive individual post-chemotherapy.
  • [MeSH-major] Cytomegalovirus Infections / virology. Fever / complications. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy. Neutropenia / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. Foscarnet .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20171139.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 364P9RVW4X / Foscarnet; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. Fujimuro M, Yokosawa H: [Regulations of gene expression and the ubiquitin-dependent pathway by human herpesvirus 8]. Tanpakushitsu Kakusan Koso; 2007 Aug;52(10 Suppl):1113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Genome, Viral. Humans. Lymphoma, AIDS-Related / virology. Proteasome Endopeptidase Complex. Sarcoma, Kaposi / virology. Signal Transduction. Transcription, Genetic. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824226.001).
  • [ISSN] 0039-9450
  • [Journal-full-title] Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme
  • [ISO-abbreviation] Tanpakushitsu Kakusan Koso
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ubiquitin; 0 / beta Catenin; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 26
  •  go-up   go-down


21. Fellner MD, Durand K, Correa RM, Redini L, Yampolsky C, Colobraro A, Sevlever G, Teyssié AR, Benetucci J, Picconi MA: Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis; 2007 Mar;11(2):172-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma.
  • OBJECTIVE: To analyze Epstein-Barr virus (EBV) load at different HIV infection stages and its relation with brain lymphoma.
  • DESIGN: A cross-sectional study was conducted on 172 HIV-infected individuals: 62 asymptomatic HIV carriers (group A), 30 HIV progressors (group B), 73 AIDS patients (group C), seven AIDS patients with brain lymphoma (group C-BL); and 26 blood donors (group BD) as healthy carriers.
  • RESULTS: PBMC-EBV levels in HIV-infected patients were higher than in the blood donors (p<0.05).
  • Similar PBMC-EBV loads were seen in HIV-infected patients with CD4+ T cell counts higher than 50/mm(3) (p>0.05), while significantly lower levels were found in cases with less than 50 cells/mm(3) (p<0.05).
  • In all HIV-infected patients, plasma-EBV load was lower than, or similar to, PBMC-EBV load, unlike 2/7 HIV-positive brain lymphoma patients.
  • CONCLUSIONS: During HIV infection PBMC-EBV load rises in comparison to healthy carriers, but decreases when immunosuppression progresses and CD4+ T cell count becomes <50/mm(3).
  • Circulating EBV is mainly cell-associated in the HIV-infected population.
  • Neither PBMC-EBV nor plasma-EBV loads would be useful to diagnose brain lymphoma in AIDS patients.
  • [MeSH-major] Brain Neoplasms / virology. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931088.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


22. Cai Q, Verma SC, Lu J, Robertson ES: Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res; 2010;78:87-142
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.
  • Kaposi's Sarcoma-associated Herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus,and is associated with the pathogenesis of Kaposi's sarcoma and two lymphoproliferative disorders known to occur frequently in AIDS patients-primary effusion lymphoma and multicentric Castleman disease.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Genes Dev. 2000 Jan 1;14(1):34-44 [10640274.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1151-7 [10666184.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):213-24 [10670545.001]
  • [Cites] J Virol. 2000 Mar;74(6):2867-75 [10684303.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 2;270(1):23-7 [10733899.001]
  • [Cites] Mol Med. 1998 Jun;4(6):402-12 [10780883.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1562-8 [10823754.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2179-83 [10854238.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] J Gen Virol. 2000 Aug;81(Pt 8):2029-38 [10900042.001]
  • [Cites] J Virol. 2000 Sep;74(17):8194-201 [10933732.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] Immunity. 2000 Sep;13(3):365-74 [11021534.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):8254-63 [11027294.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):239-47 [11089981.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] Virology. 2000 Dec 5;278(1):60-74 [11112482.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]
  • [Cites] Virology. 2001 Aug 15;287(1):62-70 [11504542.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33805-11 [11448967.001]
  • [Cites] J Virol. 2001 Oct;75(19):9509-16 [11533213.001]
  • [Cites] J Gen Virol. 2001 Oct;82(Pt 10):2393-404 [11562533.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1265-73 [11756476.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):23-9 [11786394.001]
  • [Cites] Rev Med Virol. 2002 Jan-Feb;12(1):47-63 [11787083.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1226-34 [11801659.001]
  • [Cites] J Virol. 2002 Mar;76(5):2440-8 [11836422.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Virology. 2001 Dec 20;291(2):241-59 [11878894.001]
  • [Cites] J Virol. 2002 Apr;76(7):3421-39 [11884567.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] J Virol. 2002 May;76(9):4390-400 [11932406.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] J Virol. 2002 May;76(10):4688-98 [11967286.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2602-15 [12032073.001]
  • [Cites] J Gen Virol. 2002 Jul;83(Pt 7):1535-45 [12075072.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27401-11 [12015325.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Virol. 2002 Sep;76(17):8797-807 [12163600.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Cell Growth Differ. 2002 Aug;13(8):387-95 [12193477.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):31863-7 [10542211.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]
  • [Cites] Virology. 2000 Jan 5;266(1):17-25 [10612656.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6097-102 [10626797.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):72-84 [14729610.001]
  • [Cites] Herpes. 2003 Dec;10(3):72-7 [14759339.001]
  • [Cites] Virology. 2004 Feb 20;319(2):225-36 [14980483.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):211-27 [14996505.001]
  • [Cites] FASEB J. 2004 Mar;18(3):422-7 [15003988.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Exp Mol Med. 2004 Feb 29;36(1):1-12 [15031665.001]
  • [Cites] J Virol. 2004 Apr;78(8):4207-23 [15047836.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] J Mol Med (Berl). 2004 Apr;82(4):223-31 [14991150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6 [15047889.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2774-81 [15087393.001]
  • [Cites] Curr Opin Infect Dis. 2004 Feb;17(1):53-7 [15090892.001]
  • [Cites] Blood. 2004 May 1;103(9):3465-73 [14726403.001]
  • [Cites] J Virol. 2004 Jun;78(12):6389-98 [15163732.001]
  • [Cites] J Virol. 2004 Jun;78(12):6585-94 [15163750.001]
  • [Cites] J Virol. 2004 Jul;78(13):6818-26 [15194757.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404 [15190178.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):683-5 [15220917.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Nat Rev Microbiol. 2004 Aug;2(8):656-68 [15263900.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):322-30 [15197489.001]
  • [Cites] Lancet. 2004 Aug 28-Sep 3;364(9436):740-1 [15337387.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] Virology. 2004 Oct 10;328(1):7-18 [15380353.001]
  • [Cites] J Med Virol. 2004 Nov;74(3):390-6 [15368522.001]
  • [Cites] Annu Rev Med. 2001;52:453-70 [11160789.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):15-23 [11158202.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1112-5 [11167749.001]
  • [Cites] J Gen Virol. 2001 Mar;82(Pt 3):499-506 [11172090.001]
  • [Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(5):2345-52 [11160738.001]
  • [Cites] J Virol. 2001 Mar;75(5):2435-43 [11160746.001]
  • [Cites] J Virol. 2001 Apr;75(7):3129-40 [11238840.001]
  • [Cites] J Virol. 2001 Apr;75(7):3250-8 [11238851.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):187-98 [11252894.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:906-12 [11268420.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24 [11274437.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2641-8 [11289142.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13427-32 [11154704.001]
  • [Cites] Arch Virol. 2001;146(2):403-13 [11315648.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3436-44 [11313469.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):499-516 [11313008.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):245-57 [11325605.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):833-43 [11336706.001]
  • [Cites] Blood. 2001 May 15;97(10):3244-50 [11342455.001]
  • [Cites] J Virol. 2001 Jun;75(12):5614-26 [11356969.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] J Dermatol Sci. 2001 Jul;26(3):182-93 [11390203.001]
  • [Cites] J Virol. 2001 Jul;75(13):6193-8 [11390621.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] Traffic. 2001 Jun;2(6):375-84 [11389765.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1599-606 [11413168.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):505-13 [11418689.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3311-22 [11423981.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Hum Virol. 2001 Mar-Apr;4(2):62-73 [11437316.001]
  • [Cites] J Virol. 2001 Aug;75(16):7572-82 [11462029.001]
  • [Cites] J Virol. 2005 Aug;79(16):10138-46 [16051806.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2005 Sep;79(17):10952-67 [16103147.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4840-3 [16145154.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12885-90 [16120683.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1110-7 [16043440.001]
  • [Cites] Eur J Histochem. 2005 Jul-Sep;49(3):273-84 [16216813.001]
  • [Cites] J Virol. 2005 Nov;79(21):13618-29 [16227282.001]
  • [Cites] Trends Biochem Sci. 2005 Nov;30(11):630-41 [16236519.001]
  • [Cites] J Virol. 2005 Dec;79(24):15027-37 [16306573.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Nat Immunol. 2006 Jan;7(1):33-9 [16311601.001]
  • [Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):93-8 [16364321.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):114-9 [16311516.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):168-74 [16397229.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] J Virol. 2006 Feb;80(3):1385-92 [16415016.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]
  • [Cites] J Virol. 2006 Mar;80(5):2243-56 [16474132.001]
  • [Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] J Virol. 1997 Jan;71(1):839-42 [8985427.001]
  • [Cites] Immunity. 2002 Aug;17(2):143-55 [12196286.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;269:187-201 [12224509.001]
  • [Cites] J Virol. 2002 Oct;76(20):10320-31 [12239308.001]
  • [Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]
  • [Cites] J Virol. 2002 Nov;76(22):11677-87 [12388727.001]
  • [Cites] J Virol. 2002 Dec;76(23):11880-8 [12414930.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]
  • [Cites] Curr Biol. 2002 Nov 19;12(22):1928-33 [12445386.001]
  • [Cites] AIDS. 2002 Dec 6;16(18):2473-8 [12461423.001]
  • [Cites] Trends Cell Biol. 2003 Jan;13(1):7-12 [12480335.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):7397-405 [12486118.001]
  • [Cites] J Virol. 2003 Mar;77(6):3878-81 [12610165.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9283-9 [12645526.001]
  • [Cites] J Virol. 2003 May;77(10):5578-88 [12719550.001]
  • [Cites] J Virol. 2003 Jun;77(12):6761-8 [12767996.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):129-35 [12769790.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1463-70 [12771415.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1485-91 [12771417.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] J Virol. 2003 Jul;77(14):8147-52 [12829853.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] J Virol. 2003 Sep;77(18):9738-49 [12941882.001]
  • [Cites] J Virol. 2003 Oct;77(19):10179-85 [12970403.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1113-22 [13679525.001]
  • [Cites] Annu Rev Microbiol. 2003;57:609-39 [14527293.001]
  • [Cites] J Virol. 2003 Nov;77(21):11425-35 [14557628.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8282-94 [14585985.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52406-11 [14561765.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52437-45 [14563855.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):124-36 [14702116.001]
  • [Cites] Eur J Med Res. 1998 Oct 14;3(10):461-4 [9753702.001]
  • [Cites] DNA Cell Biol. 1998 Sep;17(9):735-42 [9778032.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1358-63 [9801396.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Feb;73(2):1341-9 [9882339.001]
  • [Cites] J Virol. 1999 Feb;73(2):1438-46 [9882349.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8 [9928727.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):654-63 [9927425.001]
  • [Cites] Crit Rev Oncog. 1998;9(2):107-24 [9973245.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] J Hum Virol. 1998 Mar-Apr;1(3):207-13 [10195244.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5704-9 [10318948.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):201-9 [10343071.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):231-9 [10343074.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Virol. 1999 Jul;73(7):5722-30 [10364323.001]
  • [Cites] J Virol. 1999 Jul;73(7):6006-14 [10364352.001]
  • [Cites] J Virol. 1999 Aug;73(8):6646-60 [10400762.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] AIDS. 1999 Jul 9;13(10):1165-76 [10416519.001]
  • [Cites] J Virol. 1999 Sep;73(9):7334-42 [10438822.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):827-40 [10499921.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2004 Oct;78(20):11108-20 [15452231.001]
  • [Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]
  • [Cites] J Biol Chem. 2004 Oct 22;279(43):45093-101 [15304516.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2903-11 [15231571.001]
  • [Cites] J Virol. 2004 Nov;78(22):12566-75 [15507644.001]
  • [Cites] J Clin Lab Immunol. 1983 Sep;12(1):1-10 [6355477.001]
  • [Cites] Lancet. 1984 Mar 3;1(8375):478-80 [6142209.001]
  • [Cites] Lancet. 1984 Jun 16;1(8390):1318-20 [6145025.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6333-8 [3022918.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4068-72 [1693429.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Mar 31;183(3):1167-74 [1567395.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] Medicine (Baltimore). 1993 Jul;72(4):245-61 [8341141.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Cell Biol. 1995 Aug;130(3):507-18 [7542657.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Lancet. 1995 Nov 18;346(8986):1360-1 [7475785.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):200-3 [8567117.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 3;88(7):450-5 [8618237.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Lancet. 1996 Sep 28;348(9031):858-61 [8826812.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] AIDS. 1996 Sep;10(10):1101-5 [8874626.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] J Virol. 1996 Nov;70(11):8151-4 [8892944.001]
  • [Cites] Cell. 1996 Nov 1;87(3):447-58 [8898198.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1963-73 [16794734.001]
  • [Cites] J Virol. 2006 Aug;80(16):7965-75 [16873253.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):456-62 [16894293.001]
  • [Cites] J Virol. 2006 Sep;80(18):8909-19 [16940503.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):445-55 [16860939.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):659-62 [17001705.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2516-24 [16810301.001]
  • [Cites] J Virol. 2006 Nov;80(21):10772-86 [16928766.001]
  • [Cites] J Virol. 2006 Nov;80(21):10802-12 [16956952.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] Mol Immunol. 2007 Jan;44(1-3):11-22 [16905191.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:101-36 [17089795.001]
  • [Cites] J Gen Virol. 2006 Dec;87(Pt 12):3529-38 [17098967.001]
  • [Cites] J Infect Dis. 2007 Mar 1;195(5):645-59 [17262705.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1550-8 [17047149.001]
  • [Cites] J Virol. 2007 Mar;81(5):2449-58 [17151100.001]
  • [Cites] J Virol. 2007 Mar;81(5):2401-17 [17151125.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):245-58 [17349582.001]
  • [Cites] Nat Rev Immunol. 2007 May;7(5):391-401 [17457345.001]
  • [Cites] PLoS Pathog. 2007 Mar;3(3):e44 [17397260.001]
  • [Cites] J Virol. 2007 Aug;81(15):7941-59 [17507466.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):7003-10 [17638913.001]
  • [Cites] J Virol. 2007 Sep;81(18):9825-37 [17626102.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):452-7 [17762570.001]
  • [Cites] J Virol. 2007 Oct;81(19):10413-23 [17634230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16287-92 [17909182.001]
  • [Cites] Cell Host Microbe. 2007 Aug 16;2(2):106-18 [18005725.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] J Virol. 1997 Mar;71(3):1984-91 [9032330.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] J Virol. 1997 Jun;71(6):4187-92 [9151804.001]
  • [Cites] J Virol. 1997 Jun;71(6):4193-8 [9151805.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):748-50 [9191012.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] J Virol. 1997 Aug;71(8):5894-904 [9223479.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20313-6 [9252331.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] J Pathol. 1997 Jul;182(3):262-5 [9349227.001]
  • [Cites] Oncogene. 1997 Oct 16;15(16):1979-85 [9365244.001]
  • [Cites] Virology. 1997 Nov 10;238(1):22-9 [9375005.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2606-10 [9366576.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1517-22 [9403701.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 4;90(5):395-7 [9498490.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]
  • [Cites] Science. 1998 Apr 10;280(5361):248-53 [9535648.001]
  • [Cites] Nat Med. 1998 Apr;4(4):435-40 [9546789.001]
  • [Cites] J Virol. 1998 Jun;72(6):4980-8 [9573267.001]
  • [Cites] Trends Genet. 1998 Apr;14(4):144-50 [9594662.001]
  • [Cites] J Virol. 1998 Jul;72(7):5433-40 [9620998.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):543-8 [9679756.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):65-71 [9709306.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5219-28 [9710606.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83 [9720757.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] RNA. 2010 Aug;16(8):1540-58 [20566670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13069-74 [20615981.001]
  • [Cites] J Virol. 2010 Oct;84(19):9718-32 [20660191.001]
  • [Cites] J Virol. 2010 Nov;84(21):11134-44 [20719954.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5738-46 [10523854.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1962;18:330-63 [14481196.001]
  • [Cites] J Virol. 2004 Dec;78(24):14033-8 [15564510.001]
  • [Cites] Cancer Invest. 2004;22(5):774-86 [15581058.001]
  • [Cites] J Virol. 2005 Jan;79(2):800-11 [15613308.001]
  • [Cites] J Virol. 2005 Jan;79(2):1191-206 [15613346.001]
  • [Cites] J Virol. 2005 Feb;79(3):1397-408 [15650166.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1310-8 [15471957.001]
  • [Cites] J Virol. 2005 Feb;79(4):2637-42 [15681465.001]
  • [Cites] Science. 2005 Feb 4;307(5710):739-41 [15692053.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2067-75 [15688008.001]
  • [Cites] J Virol. 2005 Apr;79(8):4952-64 [15795281.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):771-7 [15854912.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Jul;79(13):8493-505 [15956592.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]
  • [Cites] J Virol. 2005 Aug;79(15):9912-25 [16014952.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):156-63 [16014885.001]
  • [Cites] Retrovirology. 2005;2:9 [15713234.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2430-40 [16508017.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] Mol Immunol. 2006 Apr;43(10):1665-75 [16442624.001]
  • [Cites] J Virol. 2006 Apr;80(8):4068-78 [16571823.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3658-66 [16585191.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1139-44 [16603514.001]
  • [Cites] J Virol. 2006 May;80(10):4833-46 [16641275.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1264-73 [16604194.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2717-26 [16418726.001]
  • [Cites] J Virol. 2006 Jun;80(11):5273-82 [16699007.001]
  • [Cites] J Virol. 2006 Jun;80(11):5371-82 [16699017.001]
  • [Cites] J Virol. 2006 Jun;80(12):6165-70 [16731955.001]
  • [Cites] J Virol. 2006 Jul;80(13):6534-52 [16775340.001]
  • [Cites] J Virol. 2006 Jul;80(14):7037-51 [16809309.001]
  • [Cites] Virology. 2008 Feb 5;371(1):139-54 [17964626.001]
  • [Cites] EMBO J. 2008 Feb 20;27(4):654-66 [18219272.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1751-9 [18339855.001]
  • [Cites] J Virol. 2008 Apr;82(8):4184-9 [18272573.001]
  • [Cites] AIDS. 2008 May 11;22(8):937-45 [18453853.001]
  • [Cites] J Virol. 2008 Jul;82(13):6734-46 [18417561.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4640-8 [18559509.001]
  • [Cites] J Virol. 2008 Sep;82(17):8771-9 [18579585.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4227-34 [18757778.001]
  • [Cites] J Virol. 2009 Apr;83(7):3342-64 [19158252.001]
  • [Cites] J Virol. 2009 May;83(10):4895-911 [19279100.001]
  • [Cites] J Pharmacol Exp Ther. 2009 Jun;329(3):1142-7 [19258523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 26;106(21):8683-8 [19429708.001]
  • [Cites] BioDrugs. 2009;23(2):69-75 [19489649.001]
  • [Cites] J Virol. 2009 Jul;83(14):7129-41 [19439469.001]
  • [Cites] PLoS Pathog. 2009 Jul;5(7):e1000512 [19593382.001]
  • [Cites] J Virol. 2009 Aug;83(16):8163-72 [19493995.001]
  • [Cites] Virchows Arch. 2009 Aug;455(2):159-70 [19484260.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000606 [19798430.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000616 [19816565.001]
  • [Cites] Neoplasia. 2009 Dec;11(12):1272-84 [20019835.001]
  • [Cites] J Virol. 2010 Feb;84(3):1334-47 [19906914.001]
  • [Cites] Genes Dev. 2010 Jan 15;24(2):195-205 [20080955.001]
  • [Cites] Nat Cell Biol. 2010 Feb;12(2):193-9 [20081837.001]
  • [Cites] PLoS Pathog. 2010 Jan;6(1):e1000742 [20126446.001]
  • [Cites] J Virol. 2010 Mar;84(5):2188-99 [19923183.001]
  • [Cites] J Virol. 2010 Mar;84(5):2318-30 [20032179.001]
  • [Cites] PLoS Pathog. 2010 Feb;6(2):e1000777 [20169190.001]
  • [Cites] J Virol. 2010 Mar;84(6):2697-706 [20071580.001]
  • [Cites] PLoS One. 2010;5(3):e9720 [20300531.001]
  • [Cites] Oncogene. 2010 Mar 25;29(12):1835-44 [20023696.001]
  • [Cites] J Gen Virol. 2010 May;91(Pt 5):1138-49 [20089804.001]
  • [Cites] J Virol. 2010 May;84(10):5229-37 [20219912.001]
  • [Cites] Nat Cell Biol. 2010 May;12(5):513-9 [20418869.001]
  • [Cites] Virology. 2010 Jul 20;403(1):92-102 [20451233.001]
  • [Cites] Biochem Biophys Res Commun. 2010 Jun 4;396(3):608-13 [20417616.001]
  • [Cites] Free Radic Biol Med. 2010 Aug 1;49(3):383-91 [20441790.001]
  • (PMID = 21040832.001).
  • [ISSN] 1557-8399
  • [Journal-full-title] Advances in virus research
  • [ISO-abbreviation] Adv. Virus Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA091792; United States / NIDCR NIH HHS / DE / DE014136; United States / NIDCR NIH HHS / DE / R01 DE014136; United States / NCI NIH HHS / CA / R00 CA126182-04; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / K99 CA126182; United States / NIAID NIH HHS / AI / AI067037; United States / NCI NIH HHS / CA / R00 CA126182; United States / NCI NIH HHS / CA / CA126182-03; United States / NIAID NIH HHS / AI / R01 AI067037; United States / NIDCR NIH HHS / DE / R01 DE017338; United States / NCI NIH HHS / CA / CA126182; United States / NCI NIH HHS / CA / R00 CA126182-03; United States / NIDCR NIH HHS / DE / DE17338; United States / NCI NIH HHS / CA / CA126182-04; United States / NCI NIH HHS / CA / CA072510
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS309404; NLM/ PMC3142360
  •  go-up   go-down


23. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, López-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H, GESIDA Group, GELCAB Group: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica; 2007 Feb;92(2):191-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Although doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is considered the standard chemotherapy regimen for Hodgkin's lymphoma (HL), information on the results of this therapy in human immunodeficiency (HIV)-related HL is scarce.
  • We analyzed the results of the ABVD regimen and highly active antiretroviral therapy (HAART) in patients with advanced stage, HIV-related HL.
  • DESIGN AND METHODS: From January 1996 to December 2005, 62 HIV-infected patients with newly diagnosed HL were treated in 15 Spanish hospitals.
  • INTERPRETATION AND CONCLUSIONS: In patients with advanced stage, HIV-related HL, treatment with ABVD together with HAART is feasible and effective.
  • This supports the concept that patients with HIV-related HL should be treated in the same way as immunocompetent patients if HAART, adequate supportive therapy and anti-infectious prophylaxis are given concomitantly.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Hodgkin Disease / virology. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. CD4-Positive T-Lymphocytes / metabolism. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296568.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


24. Epstein JB: Oral malignancies associated with HIV. J Can Dent Assoc; 2007 Dec;73(10):953-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral malignancies associated with HIV.
  • Advances in the management of HIV infection have resulted in significant changes in survival and in the prevalence and incidence of oral diseases found in persons infected with HIV (as discussed in other articles in this series).
  • HIV is associated with an increased risk of malignant disease that is related to immunosuppression and the activity of the HIV transactivator of transcription protein, coviral infection and exposure to carcinogens.
  • The presence of oral malignancies varies with the route of the transmission of HIV and varies geographically, based on behaviour, viral cofactors, HIV therapy and genetic variation.
  • [MeSH-major] Dental Care for Chronically Ill. HIV Infections / complications. Mouth Neoplasms / etiology
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / etiology. Humans. Immunosuppression / adverse effects. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / etiology. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / etiology. rev Gene Products, Human Immunodeficiency Virus / physiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275699.001).
  • [ISSN] 1488-2159
  • [Journal-full-title] Journal (Canadian Dental Association)
  • [ISO-abbreviation] J Can Dent Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / rev Gene Products, Human Immunodeficiency Virus
  •  go-up   go-down


25. Boccara O, Prost-Squarcioni C, Battistella M, Brousse N, Rongioletti F, Fraitag S: Calcinosis cutis: a rare reaction to subcutaneous injections of calcium-containing heparin in patients with renal failure. Am J Dermatopathol; 2010 Feb;32(1):52-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first patient developed firm erythematous nodules on his thighs and right arm, in a context of disseminated tuberculosis and acute severe renal failure related to human immunodeficiency virus nephropathy.
  • The second patient developed similar lesions at injection sites of calcium-containing heparin, in a context of non-Hodgkin lymphoma and end-stage renal failure.
  • [MeSH-minor] AIDS-Associated Nephropathy / complications. AIDS-Associated Nephropathy / metabolism. AIDS-Associated Nephropathy / pathology. AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / pathology. Adult. Aged. Calcium / blood. Female. Humans. Injections, Subcutaneous / adverse effects. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / pathology. Male. Phosphates / blood. Skin / metabolism. Skin / pathology. Tuberculosis / complications. Tuberculosis / metabolism. Tuberculosis / pathology. Withholding Treatment

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851086.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Phosphates; 37270-89-6 / calcium heparin; 9005-49-6 / Heparin; SY7Q814VUP / Calcium
  •  go-up   go-down


26. Cornejo-Juárez P, Volkow-Fernández P, Avilés-Salas A, Calderón-Flores E: AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico. Rev Invest Clin; 2008 Sep-Oct;60(5):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
  • BACKGROUND: Non-Hodgkin lymphoma (NHL) associated with HIV became an AIDS-defining condition early in the epidemic and remains the second most common malignancy in patients with AIDS.
  • With the advent of highly active antiretroviral therapy (HAART), the incidence and mortality of AIDS-related opportunistic infections and Kaposi's sarcoma has fallen dramatically, this trend is not observed so clearly for NHL.
  • Our objective was to review the clinical spectrum of patients with AIDS-associated NHL and to analyze the impact of HAART on survival at an oncological tertiary center.
  • MATERIAL AND METHODS: We reviewed all medical records and histopathologic tissue of patients with HIV-associated NHL seen from January 1990 to September 2007 at the Instituto Nacional de Cancerologia in Mexico City.
  • RESULTS: Eighty seven HIV-positive patients were diagnosed with NHL (diffuse large B-cell lymphoma n=69; Burkitt-like n=8; pleomorphic large cell n=7; low-grade n=2, and angiocentric n=1).
  • CONCLUSIONS: Patients with NHL-HIV who were able to receive treatment with HAART and were sufficiently healthy to receive optimal chemotherapy treatment showed a significantly better prognosis.
  • [MeSH-major] Cancer Care Facilities / statistics & numerical data. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227434.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


27. Tam CS, Seymour JF: The infectious consequences of rituximab addition to fludarabine-containing regimens. Blood; 2006 Apr 1;107(7):3013-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • (PMID = 16554491.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


28. Vaghefi P, Martin A, Prévot S, Charlotte F, Camilleri-Broët S, Barli E, Davi F, Gabarre J, Raphael M, Poirel HA: Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status. AIDS; 2006 Nov 28;20(18):2285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status.
  • BACKGROUND: The pathologic heterogeneity of AIDS related lymphomas (ARL) reflects several pathogenic mechanisms: chronic antigenic stimulation, Epstein-Barr virus (EBV) infection, and genomic abnormalities.
  • Genetic abnormalities, known to play a major role in lymphomas of non-immunocompromised patients, are not well characterized in ARL.
  • DNA-CNC tended to be more frequent in EBV-positive lymphomas with latency type II/III than in EBV-positive latency I or EBV-negative lymphomas.
  • Most chromosomal regions affected in HIV-related lymphoma were similar to those already reported in HIV-negative lymphomas.
  • The results suggested an inverse relationship between EBV infection (latency II/III), associated with deep acquired immune suppression, and the number of chromosomal alterations which may be explained by a direct role of viral proteins in lymphomagenesis by activation of signalling pathways without needing several genomic alterations.
  • [MeSH-major] Epstein-Barr Virus Infections / genetics. Lymphoma, AIDS-Related / genetics
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / complications. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Chromosome Aberrations. Chromosomes, Human / genetics. Clone Cells / immunology. DNA, Viral / genetics. Female. Genes, Viral / genetics. Genes, Viral / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / immunology. Male. Middle Aged. Nucleic Acid Hybridization / methods

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117014.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


29. Behler CM, Kaplan LD: Advances in the management of HIV-related non-Hodgkin lymphoma. Curr Opin Oncol; 2006 Sep;18(5):437-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of HIV-related non-Hodgkin lymphoma.
  • PURPOSE OF REVIEW: Human immunodeficiency virus infection is associated with an increased risk of non-Hodgkin lymphoma.
  • Even with a decrease in AIDS-defining illnesses after the advent of highly active antiretroviral therapy, HIV-associated non-Hodgkin lymphoma remains an important problem.
  • RECENT FINDINGS: Low CD4+ T-lymphocyte count, disease stage, performance status, serum lactate dehydrogenase, and number of extranodal sites of disease are all important prognostic factors for HIV-non-Hodgkin lymphoma.
  • Recent studies have examined the role of infusional chemotherapy, as well as immunotherapy, in the treatment of aggressive HIV-non-Hodgkin lymphoma, and autologous stem cell transplantation for relapsed or refractory HIV-non-Hodgkin lymphoma.
  • New developments in the association of viral infection and pathogenesis of certain subtypes of HIV-non-Hodgkin lymphoma have also recently been reported.
  • SUMMARY: Outcomes of HIV-non-Hodgkin lymphoma are improving with the routine use of highly active antiretroviral therapy and combination chemotherapy.
  • For aggressive HIV-non-Hodgkin lymphoma, infusional chemotherapy regimens are well tolerated and lead to complete response in about 50-75% of cases and a 2-3 years overall survival of 40-60%.
  • HIV-associated Burkitt lymphoma should be treated with an intensive regimen rather than standard cyclophosphamide, doxorubicin, vincristine, prednisone-like chemotherapy.
  • Autologous stem cell transplantation should be considered for selected patients with relapsed or refractory HIV-non-Hodgkin lymphoma.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894290.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 65
  •  go-up   go-down


30. Ramírez-Olivencia G, Valencia-Ortega ME, Martin-Carbonero L, Moreno-Celda V, González-Lahoz J: [Malignancies in HIV infected patients: study of 139 cases]. Med Clin (Barc); 2009 Nov 21;133(19):729-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignancies in HIV infected patients: study of 139 cases].
  • [Transliterated title] Tumores en pacientes con infección por el virus de la inmunodeficiencia humana: estudio de 139 casos.
  • BACKGROUND AND OBJECTIVE: Since the introduction of highly active antiretroviral therapy (HAART), the natural history of HIV infection has been altered by an increasing survival.
  • Following this, neoplastic diseases have become more common in HIV positive patients.
  • The purpose of this study was to describe the types of tumor, clinical features and prognosis of HIV infected patients with malignant diseases.
  • Information was collected on age, sex, risk factors for HIV, HBV/HCV coinfection, malignancies, diagnosis of AIDS, viral load and CD4 cell counts at diagnosis, antiretroviral therapy and mortality.
  • A total of 139 HIV-infected patients were identified who had at least one malignancy.
  • RESULTS: Types of malignancy were Kaposi's Sarcoma (n=43, 30.9%); non-Hodgkin lymphoma (n=42, 30.2%); gynecologic malignancy (n=16, 11.5%); Hodgkin's disease (n=15, 10.8%); hepatocellular carcinoma (n=7, 5%) and others (n=16, 11.5%).
  • Risk factor for HIV was MSM (n=64;46%), IDUs (n=48; 34.5%) and heterosexual (n=26; 18.7%).
  • CONCLUSIONS: Increased survival of HIV-infected patients receiving HAART makes it possible the development of secondary tumors and AIDS- unrelated malignancies, sometimes related to another virus.
  • [MeSH-major] HIV Infections / complications. Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880148.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T, Gaya A, Nelson M, Stebbing J: A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med; 2005 Aug 16;143(4):265-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
  • BACKGROUND: The established International Prognostic Index for lymphomas has not included patients with systemic AIDS-related non-Hodgkin lymphoma.
  • OBJECTIVE: To establish the most appropriate prognostic index for use in patients with systemic AIDS-related non-Hodgkin lymphoma.
  • DESIGN: A prospective study involving univariate and multivariable analyses of patients with AIDS-related non-Hodgkin lymphoma whose data were used to examine standard and new criteria for survival after diagnosis.
  • SETTING: The Chelsea and Westminster cohort of HIV-1-infected persons.
  • PATIENTS: 9621 HIV-positive patients, 111 in whom AIDS-related non-Hodgkin lymphoma was treated after 1996, in the era of highly active antiretroviral therapy (HAART).
  • RESULTS: Survival of patients with AIDS-related non-Hodgkin lymphoma has increased in the HAART era (log-rank chi-square, 9.23; P = 0.002).
  • Regression modeling for patients in whom disease was diagnosed after 1996 revealed only 2 independent predictors of death: International Prognostic Index risk group and CD4 cell count.
  • CONCLUSIONS: For patients with AIDS-related non-Hodgkin lymphoma that was diagnosed in the era of HAART, application of the International Prognostic Index remains useful.
  • Patients who present with AIDS-related non-Hodgkin lymphoma and a low CD4 cell count have a poor prognosis; this information can be used to guide therapeutic options.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality


32. Levine AM: Management of AIDS-related lymphoma. Curr Opin Oncol; 2008 Sep;20(5):522-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related lymphoma.
  • PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.
  • Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.
  • RECENT FINDINGS: Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients.
  • The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed.
  • The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results.
  • High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.
  • Addition of rituximab is associated with improved response rates, without an increase in infections.
  • Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.
  • Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106654.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


33. Baehring JM, Hochberg FH: Primary lymphoma of the nervous system. Cancer J; 2006 Jan-Feb;12(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the nervous system.
  • This review article provides guidelines for the diagnosis, staging, and management of primary nervous system lymphoma based on the results of clinical trials conducted during the last decade.
  • Recent progress in our understanding of the pathogenesis of primary nervous system lymphoma is summarized, and implications of these findings for the development of diagnostic tools and new therapeutic strategies are outlined.
  • We performed a search of the PubMed database (National Center for Biotechnology Information) for articles on primary nervous system lymphoma published between 1970 and May 2005.
  • Primary nervous system lymphoma affects the brain, eye, and meninges as well as cranial, spinal, and peripheral nerves.
  • Although important lessons have been learned from the pathogenesis of extraneural non-Hodgkin's lymphoma, the unique organotropism of primary nervous system lymphoma remains poorly understood.
  • Long-term survival and, in selected cases, even a cure are possible in primary nervous system lymphoma.
  • A deeper understanding of the pathogenesis of primary nervous system lymphoma may reveal new therapeutic targets.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Nervous System Neoplasms / diagnosis. Nervous System Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Eye Neoplasms / therapy. Humans. Lymphoma, AIDS-Related / therapy. Magnetic Resonance Imaging. Methotrexate / therapeutic use. Organ Transplantation. Radiotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613654.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 108
  •  go-up   go-down


34. Noy A: Update on HIV lymphoma. Curr Oncol Rep; 2007 Sep;9(5):384-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on HIV lymphoma.
  • In industrialized nations people infected with HIV remain at increased risk for malignancies despite highly active antiretroviral therapy.
  • In these countries, lymphoma is the most common HIV-associated malignancy.
  • The majority of investigation has been in diffuse large B cell lymphoma, with infusional therapy remaining promising but cumbersome.
  • Rituximab likely improves complete response rates, and, possibly overall survival, but is likely associated with increased infections in a subset of patients with very low CD4 counts.
  • Biologic insights have been attained in the spectrum of HIV-associated non-Hodgkin's lymphoma, Hodgkin's lymphoma, and virologic coinfections.
  • Overall, the outcome for non-Hodgkin's lymphoma and Hodgkin's lymphoma in the setting of HIV continues to improve as insights into the pathophysiology and treatment advance.
  • [MeSH-major] Lymphoma, AIDS-Related

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Exp Hematol. 2005 Apr;33(4):487-94 [15781340.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1598-602 [17106439.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Mar;6(5):399-402 [16640817.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):e21-5 [16421782.001]
  • [Cites] Ann Hematol. 2005 Oct;84(10):661-6 [15875183.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):1022-7 [15824995.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Mar;21(3):214-20 [15795527.001]
  • [Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1492-9 [11920506.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1196-205 [12973843.001]
  • [Cites] Blood. 2006 Apr 1;107(7):3014-5 [16554492.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Sep;26(8):1973-9 [16155145.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3325-30 [11013271.001]
  • [Cites] Transplantation. 2005 Sep 15;80(5):673-82 [16177644.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3857-9 [11739198.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3412-4 [16597601.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8116-7 [16258111.001]
  • [Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1891-7 [15550484.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):161-3 [15756687.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):293-9 [15980688.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Eur J Haematol. 2005 Jan;74(1):70-2 [15613110.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3214-8 [17209054.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):207-15 [15621803.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8132-3; author reply 8133-4 [16258119.001]
  • [Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]
  • [Cites] HIV Med. 2005 Jan;6(1):21-6 [15670248.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Haematologica. 2005 Jul;90(7):990-2 [15996943.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Clin Infect Dis. 2006 Feb 1;42(3):411-7 [16392091.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] J Cell Biol. 2003 Jun 9;161(5):839-43 [12796473.001]
  • [Cites] Virology. 2005 Nov 10;342(1):38-46 [16122775.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4423-7 [14581441.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8477-82 [16230675.001]
  • (PMID = 17706167.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 52
  •  go-up   go-down


35. Castillo J, Perez K, Milani C, Dezube BJ, Pantanowitz L: Peripheral T-cell lymphomas in HIV-infected individuals: a comprehensive review. J HIV Ther; 2009 Jun;14(2):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphomas in HIV-infected individuals: a comprehensive review.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839365.001).
  • [ISSN] 1462-0308
  • [Journal-full-title] Journal of HIV therapy
  • [ISO-abbreviation] J HIV Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 87
  •  go-up   go-down


36. Cassoni A, Ali U, Cave J, Edwards SG, Ramsay A, Miller RF, Lee SM: Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. J Clin Oncol; 2008 Nov 10;26(32):5297-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Lymphoma, AIDS-Related / radiotherapy. Lymphoma, Primary Effusion / radiotherapy

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854561.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Beadsworth MB, Cohen D, Ratcliffe L, Jenkins N, Taylor W, Campbell F, Beeching NJ, Azadeh B: Autopsies in HIV: still identifying missed diagnoses. Int J STD AIDS; 2009 Feb;20(2):84-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autopsies in HIV: still identifying missed diagnoses.
  • This study reviews the deaths and autopsies carried out over 23 years, 1983-2005, in a British Infection Unit in HIV patients.
  • Of 115 HIV patients known to have died, we obtained data on 93%.
  • Lymphoma was overdiagnosed.
  • [MeSH-major] AIDS-Related Opportunistic Infections. Autopsy / statistics & numerical data. HIV Infections
  • [MeSH-minor] Adult. Aged. Cause of Death. Female. Great Britain. HIV-1. Humans. Male. Middle Aged


38. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R: Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst; 2009;26(6):523-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. DNA / administration & dosage. Drug Carriers / adverse effects. Drug Carriers / chemistry. Drug Delivery Systems. Drug-Related Side Effects and Adverse Reactions. Humans. Liposomes. Nanotechnology

  • MedlinePlus Health Information. consumer health - Medicines.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Control Release. 2003 Dec 12;93(3):271-82 [14644577.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6551-9 [14695160.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1002:78-89 [14751825.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1100-11 [14871990.001]
  • [Cites] J Infect Dis. 2004 Mar 15;189(6):1024-34 [14999606.001]
  • [Cites] Hum Gene Ther. 2002 Feb 10;13(3):469-81 [11860713.001]
  • [Cites] J Med Chem. 2004 Mar 25;47(7):1694-703 [15027860.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):665-70 [15033677.001]
  • [Cites] Biophys J. 2004 Apr;86(4):2615-29 [15041697.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 30;317(2):515-21 [15063787.001]
  • [Cites] Biomed Pharmacother. 2004 Apr;58(3):168-72 [15082339.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1055-8 [15094205.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1177-92 [15094214.001]
  • [Cites] Adv Drug Deliv Rev. 2004 May 7;56(9):1257-72 [15109768.001]
  • [Cites] Invest New Drugs. 2004 Aug;22(3):263-75 [15122073.001]
  • [Cites] Chem Rev. 2004 Jun;104(6):2901-37 [15186184.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2662-70 [15226333.001]
  • [Cites] Gene Ther. 2004 Oct;11(19):1434-40 [15229629.001]
  • [Cites] Langmuir. 2004 Sep 28;20(20):8839-45 [15379515.001]
  • [Cites] Eur J Pharm Biopharm. 2004 Nov;58(3):673-80 [15451544.001]
  • [Cites] J Mol Biol. 1965 Aug;13(1):238-52 [5859039.001]
  • [Cites] Biochem Soc Trans. 1975;3(5):613-8 [53164.001]
  • [Cites] Biophys J. 1976 Jan;16(1):1-11 [1244886.001]
  • [Cites] Biophys J. 1976 Jan;16(1):13-26 [1244887.001]
  • [Cites] Science. 1978 Dec 22;202(4374):1290-3 [364652.001]
  • [Cites] J Immunol. 1979 Feb;122(2):585-91 [368242.001]
  • [Cites] Biochim Biophys Acta. 1981 Feb 23;663(2):506-15 [7213783.001]
  • [Cites] Biochem Biophys Res Commun. 1981 Jul 16;101(1):131-6 [7283995.001]
  • [Cites] Biochim Biophys Acta. 1981 Nov 6;648(2):192-8 [7306536.001]
  • [Cites] FEBS Lett. 1983 Apr 18;154(2):373-7 [6832376.001]
  • [Cites] Br J Pharmacol. 2009 May;157(2):166-78 [19459843.001]
  • [Cites] Expert Opin Drug Deliv. 2009 Jun;6(6):553-65 [19435406.001]
  • [Cites] Bioconjug Chem. 2009 Jun;20(6):1201-8 [19435362.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):992-1000 [19057023.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Aug 1;238(3):280-8 [19379767.001]
  • [Cites] Curr Opin Chem Biol. 2009 Jun;13(3):256-62 [19419901.001]
  • [Cites] Bioconjug Chem. 2009 Jul;20(7):1404-11 [19534457.001]
  • [Cites] Curr Drug Deliv. 2009 Jul;6(3):217-26 [19604135.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Aug;18(8):1197-218 [19604121.001]
  • [Cites] Cancer. 2009 Aug 1;115(15):3475-82 [19536896.001]
  • [Cites] Mol Pharm. 2009 Jul-Aug;6(4):1041-51 [19366234.001]
  • [Cites] J Biomech Eng. 2009 Jul;131(7):074005 [19655996.001]
  • [Cites] J Pharm Pharmacol. 2009 Aug;61(8):1013-9 [19703344.001]
  • [Cites] Biomaterials. 2009 Oct;30(30):6055-64 [19665223.001]
  • [Cites] Mol Pharm. 2009 Sep-Oct;6(5):1264-76 [19432455.001]
  • [Cites] Chem Phys Lipids. 2009 Nov;162(1-2):1-16 [19703435.001]
  • [Cites] J Control Release. 2010 Feb 25;142(1):108-21 [19819275.001]
  • [Cites] Lung Cancer. 2010 May;68(2):240-7 [19628292.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 May;66(1):43-52 [19779718.001]
  • [Cites] J Liposome Res. 2010 Jun;20(2):147-59 [19848552.001]
  • [Cites] J Liposome Res. 2008;18(2):145-57 [18569449.001]
  • [Cites] Infect Immun. 2000 Jan;68(1):54-63 [10603368.001]
  • [Cites] Hum Gene Ther. 1999 Dec 10;10(18):2941-52 [10609655.001]
  • [Cites] J Drug Target. 1999;7(2):101-12 [10617296.001]
  • [Cites] Crit Rev Biotechnol. 1999;19(4):317-57 [10723627.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1197-201 [10728674.001]
  • [Cites] Int J Pharm. 2000 Apr 20;199(2):167-77 [10802410.001]
  • [Cites] Int J Pharm. 1999 Nov 10;190(1):49-56 [10528096.001]
  • [Cites] Methods Mol Med. 2005;109:389-402 [15585933.001]
  • [Cites] Pharm Res. 2004 Dec;21(12):2153-7 [15648245.001]
  • [Cites] Nat Rev Drug Discov. 2005 Feb;4(2):145-60 [15688077.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205 [15717745.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):e48 [15026537.001]
  • [Cites] Prog Lipid Res. 2005 Jan;44(1):68-97 [15748655.001]
  • [Cites] J Org Chem. 2005 Apr 1;70(7):2606-15 [15787550.001]
  • [Cites] Langmuir. 2004 Mar 16;20(6):2416-23 [15835704.001]
  • [Cites] J Colloid Interface Sci. 2005 May 15;285(2):590-8 [15837476.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3465-74 [15867249.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3567-73 [15867261.001]
  • [Cites] Biotechnol Prog. 2005 Jan-Feb;21(1):205-20 [15903260.001]
  • [Cites] Biotechnol Prog. 2005 Jan-Feb;21(1):221-32 [15903261.001]
  • [Cites] Chem Phys Lipids. 2005 Jun;135(2):117-29 [15921973.001]
  • [Cites] Chem Commun (Camb). 2005 Jun 28;(24):3021-3 [15959571.001]
  • [Cites] Tuberculosis (Edinb). 2005 Jul;85(4):227-34 [15922668.001]
  • [Cites] Eur J Pharm Biopharm. 2005 Aug;60(3):361-72 [15996577.001]
  • [Cites] Leuk Lymphoma. 2005 Jun;46(6):795-802 [16019523.001]
  • [Cites] J Drug Target. 2005 Apr;13(3):179-87 [16036306.001]
  • [Cites] Curr Opin Chem Biol. 2005 Aug;9(4):343-6 [15967706.001]
  • [Cites] Langmuir. 2005 Aug 2;21(16):7476-82 [16042482.001]
  • [Cites] Bioorg Med Chem. 2005 Sep 1;13(17):5043-54 [15955702.001]
  • [Cites] Eur J Pharm Biopharm. 2005 Sep;61(1-2):77-86 [16011893.001]
  • [Cites] Langmuir. 2005 Aug 16;21(17):7638-45 [16089364.001]
  • [Cites] J Control Release. 2005 Oct 3;107(2):262-75 [16125816.001]
  • [Cites] J Control Release. 2005 Nov 2;108(1):112-20 [16169111.001]
  • [Cites] Pharm Res. 2005 Nov;22(11):1906-17 [16088429.001]
  • [Cites] J Med Chem. 2005 Nov 17;48(23):7305-14 [16279790.001]
  • [Cites] Curr Drug Deliv. 2004 Jul;1(3):299-312 [16305392.001]
  • [Cites] Curr Drug Deliv. 2005 Oct;2(4):353-62 [16305438.001]
  • [Cites] Bone Marrow Transplant. 2000 Apr;25(8):879-84 [10808210.001]
  • [Cites] Eur J Pharm Biopharm. 2000 Jul;50(1):161-77 [10840199.001]
  • [Cites] Pharmacol Res. 2000 Oct;42(4):337-43 [10987994.001]
  • [Cites] Int J Pharm. 2000 Sep 15;205(1-2):15-21 [11000538.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 16;276(1):169-73 [11006101.001]
  • [Cites] Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S81-91 [11033430.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1444-54 [11230490.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):139-48 [11311989.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):165-96 [11311991.001]
  • [Cites] J Pharm Sci. 2001 Jun;90(6):667-80 [11357170.001]
  • [Cites] J Control Release. 2001 Jul 6;74(1-3):129-34 [11489489.001]
  • [Cites] Biochim Biophys Acta. 2001 Oct 1;1514(2):303-17 [11557029.001]
  • [Cites] Annu Rev Biomed Eng. 2000;2:339-76 [11701516.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 1;1515(2):167-76 [11718672.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Dec 31;53(3):273-84 [11744172.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Dec 31;53(3):285-305 [11744173.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):717-26 [11745468.001]
  • [Cites] Biophys J. 2002 Apr;82(4):2101-10 [11916866.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1172-81 [11948130.001]
  • [Cites] Langmuir. 2008 Jun 1;24(13):6965-80 [18512883.001]
  • [Cites] Expert Opin Biol Ther. 2008 Aug;8(8):1063-70 [18613759.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9343-8 [18607000.001]
  • [Cites] Int J Pharm. 2008 Sep 1;361(1-2):239-44 [18586075.001]
  • [Cites] J Drug Target. 2008 Aug;16(7):605-10 [18686132.001]
  • [Cites] Biomaterials. 2008 Oct;29(30):4129-36 [18667234.001]
  • [Cites] Int J Biol Macromol. 2008 Oct 1;43(3):320-4 [18619484.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Sep;5(9):1003-25 [18754750.001]
  • [Cites] Pharm Res. 2008 Oct;25(10):2262-71 [18516666.001]
  • [Cites] Curr Top Med Chem. 2008;8(14):1165-79 [18855703.001]
  • [Cites] Biomaterials. 2009 Jan;30(2):226-32 [18851881.001]
  • [Cites] Biochim Biophys Acta. 2008 Dec;1778(12):2749-56 [18762164.001]
  • [Cites] Drug Deliv. 2003 Oct-Dec;10(4):245-50 [14612340.001]
  • [Cites] Biochim Biophys Acta. 2003 Oct 31;1617(1-2):10-21 [14637015.001]
  • [Cites] Chem Commun (Camb). 2006 Sep 14;(34):3622-4 [17047785.001]
  • [Cites] J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3215-21 [17048539.001]
  • [Cites] Pharm Res. 2007 Jan;24(1):1-16 [17109211.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1768(1):21-9 [17046711.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):201-8 [16941075.001]
  • [Cites] Invest New Drugs. 2007 Apr;25(2):155-9 [16957835.001]
  • [Cites] Biochem Soc Trans. 2007 Feb;35(Pt 1):61-7 [17233602.001]
  • [Cites] Nanomedicine. 2005 Jun;1(2):101-9 [17292064.001]
  • [Cites] Eur J Pharm Biopharm. 2007 Mar;65(3):300-8 [17156986.001]
  • [Cites] Drug Deliv. 2007 Feb;14(2):61-7 [17364869.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):716-21 [17301073.001]
  • [Cites] Langmuir. 2007 Apr 10;23(8):4634-41 [17355159.001]
  • [Cites] Colloids Surf B Biointerfaces. 2007 May 15;57(1):75-80 [17303394.001]
  • [Cites] Drug Deliv. 2007 Mar;14(3):171-5 [17454037.001]
  • [Cites] J Biotechnol. 2007 May 31;130(1):85-94 [17442442.001]
  • [Cites] Biol Pharm Bull. 2007 May;30(5):972-8 [17473445.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul;1768(7):1796-804 [17531950.001]
  • [Cites] Int J Pharm. 2007 Aug 1;340(1-2):198-206 [17482778.001]
  • [Cites] J Pharm Pharmacol. 2007 Jul;59(7):935-40 [17637187.001]
  • [Cites] Adv Drug Deliv Rev. 2007 Jul 10;59(6):491-504 [17532091.001]
  • [Cites] Adv Drug Deliv Rev. 2007 Jul 10;59(6):478-90 [17543416.001]
  • [Cites] Adv Drug Deliv Rev. 2007 Jul 10;59(6):522-30 [17602783.001]
  • [Cites] Biophys J. 2007 Oct 15;93(8):2609-21 [17573422.001]
  • [Cites] Anticancer Drugs. 2007 Nov;18(10):1189-200 [17893520.001]
  • [Cites] Pharm Res. 2007 Dec;24(12):2402-11 [17828616.001]
  • [Cites] Colloids Surf B Biointerfaces. 2007 Nov 15;60(2):174-9 [17656075.001]
  • [Cites] Biomaterials. 2008 Jan;29(3):359-69 [17964645.001]
  • [Cites] Int J Nanomedicine. 2007;2(3):289-300 [18019829.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Jan;5(1):25-44 [18095927.001]
  • [Cites] Retina. 2008 Jan;28(1):147-9 [18185152.001]
  • [Cites] Urol Oncol. 2008 Jan-Feb;26(1):74-85 [18190835.001]
  • [Cites] Biochem Int. 1985 Mar;10(3):327-36 [2990474.001]
  • [Cites] J Cell Biochem. 1985;28(1):23-9 [4030900.001]
  • [Cites] Biochim Biophys Acta. 1986 Mar 27;856(1):36-40 [3955034.001]
  • [Cites] Methods Biochem Anal. 1988;33:337-462 [3282152.001]
  • [Cites] Chem Phys Lipids. 1988 Nov;49(1-2):39-47 [3233710.001]
  • [Cites] Prog Lipid Res. 1988;27(3):153-75 [3151021.001]
  • [Cites] Science. 1989 Sep 22;245(4924):1371-4 [2781283.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):444-8 [1988944.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4 [1763060.001]
  • [Cites] J Antimicrob Chemother. 1991 Oct;28 Suppl B:83-91 [1778895.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Sep;36(9):1978-80 [1416890.001]
  • [Cites] Biochim Biophys Acta. 1993 Sep 19;1151(2):201-15 [8373796.001]
  • [Cites] J Biol Chem. 1993 Nov 25;268(33):24847-54 [8227046.001]
  • [Cites] J Liposome Res. 2008;18(4):293-307 [18937120.001]
  • [Cites] PDA J Pharm Sci Technol. 2008 Sep-Oct;62(5):362-79 [19055232.001]
  • [Cites] J Control Release. 2009 Jan 19;133(2):132-8 [18929605.001]
  • [Cites] Recent Pat Drug Deliv Formul. 2008;2(2):120-35 [19075903.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8161-8 [19088031.001]
  • [Cites] Nanomedicine (Lond). 2009 Jan;4(1):105-18 [19093899.001]
  • [Cites] Biophys Chem. 2009 Feb;139(2-3):75-83 [19010585.001]
  • [Cites] ChemMedChem. 2008 Dec;3(12):1839-43 [19012296.001]
  • [Cites] Chem Phys Lipids. 2009 Feb;157(2):94-103 [19094974.001]
  • [Cites] J Phys Chem B. 2009 Jan 29;113(4):1143-52 [19123825.001]
  • [Cites] Nat Rev Drug Discov. 2008 Sep;7(9):771-82 [18758474.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(5):872-97 [19142939.001]
  • [Cites] Nanomedicine (Lond). 2009 Feb;4(2):177-91 [19193184.001]
  • [Cites] Pharm Res. 2009 Mar;26(3):529-38 [19015959.001]
  • [Cites] Biomacromolecules. 2009 Feb 9;10(2):197-209 [19123775.001]
  • [Cites] Eur J Pharm Biopharm. 2009 Feb;71(2):161-72 [18824097.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1973-80 [19276264.001]
  • [Cites] Nat Mater. 2009 Apr;8(4):331-6 [19234444.001]
  • [Cites] Chem Phys Lipids. 1999 Jun;99(2):125-37 [10390836.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 27;262(2):406-10 [10462488.001]
  • [Cites] Acc Chem Res. 2008 Jan;41(1):120-9 [17655275.001]
  • [Cites] Int J Nanomedicine. 2007;2(4):595-607 [18203427.001]
  • [Cites] J Control Release. 2008 Feb 18;126(1):50-8 [18068849.001]
  • [Cites] J Control Release. 2008 Mar 20;126(3):187-204 [18261822.001]
  • [Cites] Toxicol Pathol. 2008 Jan;36(1):21-9 [18337218.001]
  • [Cites] J Liposome Res. 2008;18(1):21-9 [18348069.001]
  • [Cites] J Control Release. 2008 Apr 21;127(2):97-109 [18313785.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):761-9 [17957183.001]
  • [Cites] Int J Pharm. 2008 Jun 5;357(1-2):272-9 [18329201.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):924-31 [18464112.001]
  • [Cites] Chem Phys Lipids. 2008 Jun;153(2):85-97 [18316039.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Jun 30;60(10):1193-208 [18474406.001]
  • [Cites] Pharm Res. 2008 Jul;25(7):1521-30 [18172580.001]
  • [Cites] Biochim Biophys Acta. 1994 Jan 3;1189(1):96-100 [8305465.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jul 29;202(2):673-9 [8048936.001]
  • [Cites] Biochim Biophys Acta. 1994 Aug 3;1193(2):247-54 [8054346.001]
  • [Cites] Biochim Biophys Acta. 1995 Feb 15;1233(2):134-44 [7865538.001]
  • [Cites] FEBS Lett. 1995 Nov 13;375(1-2):113-6 [7498457.001]
  • [Cites] Biochemistry. 1996 Feb 27;35(8):2618-24 [8611565.001]
  • [Cites] Mol Med Today. 1996 Jun;2(6):242-9 [8796897.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):66-75 [8993319.001]
  • [Cites] AIDS Patient Care STDS. 1996 Apr;10(2):135 [11361702.001]
  • [Cites] Pharm Res. 1997 Apr;14(4):458-62 [9144731.001]
  • [Cites] Nature. 1997 Jun 5;387(6633):580-3 [9177344.001]
  • [Cites] Drugs. 1997;54 Suppl 4:8-14 [9361956.001]
  • [Cites] Drugs. 1997;54 Suppl 4:15-21 [9361957.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3320-30 [9699662.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 1998;15(6):587-627 [9883391.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):723-30 [10048974.001]
  • [Cites] Clin Infect Dis. 1999 Jan;28(1):42-8; discussion 49-51 [10028069.001]
  • [Cites] Bioconjug Chem. 1999 Mar-Apr;10(2):289-98 [10077479.001]
  • [Cites] Curr Drug Deliv. 2005 Oct;2(4):363-8 [16305439.001]
  • [Cites] Curr Drug Deliv. 2005 Oct;2(4):369-81 [16305440.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Eur J Pharm Sci. 2006 Feb;27(2-3):226-36 [16298113.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):120-7 [16331634.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):117-24 [16409130.001]
  • [Cites] Langmuir. 2004 Jul 6;20(14):5969-77 [16459618.001]
  • [Cites] Org Biomol Chem. 2006 May 7;4(9):1730-40 [16633565.001]
  • [Cites] Int J Pharm. 2006 May 11;314(1):83-9 [16563671.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):818-24 [16648551.001]
  • [Cites] Pharm Dev Technol. 2006;11(2):153-7 [16749525.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):205-13 [16754340.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6732-40 [16818648.001]
  • [Cites] Blood. 2002 Jul 15;100(2):594-602 [12091353.001]
  • [Cites] Pharm Res. 2002 Jun;19(6):875-80 [12134960.001]
  • [Cites] Acta Clin Belg. 2002 Mar-Apr;57(2):53-7 [12152239.001]
  • [Cites] Int J Pharm. 2002 Aug 21;242(1-2):121-8 [12176234.001]
  • [Cites] Chem Commun (Camb). 2001 Dec 7;(23):2442-3 [12240005.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):750-63 [12360278.001]
  • [Cites] Cell Mol Biol Lett. 2002;7(3):889-94 [12378272.001]
  • [Cites] Expert Opin Pharmacother. 2002 Dec;3(12):1739-51 [12472371.001]
  • [Cites] Mol Cancer Ther. 2002 Mar;1(5):337-46 [12489850.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):86-92 [12517782.001]
  • [Cites] Chem Rev. 2003 Jan;103(1):53-69 [12517181.001]
  • [Cites] Int J Pharm. 2003 Mar 18;254(1):55-8 [12615409.001]
  • [Cites] Clin Pharmacokinet. 2003;42(5):419-36 [12739982.001]
  • [Cites] Acc Chem Res. 2003 May;36(5):335-41 [12755643.001]
  • [Cites] Prog Lipid Res. 2003 Sep;42(5):439-62 [12814645.001]
  • [Cites] Eur J Pharm Biopharm. 2003 Jul;56(1):67-72 [12837483.001]
  • [Cites] J Control Release. 2003 Sep 4;91(3):417-29 [12932719.001]
  • [Cites] J Am Chem Soc. 2003 Oct 22;125(42):12680-1 [14558795.001]
  • [Cites] Bull Exp Biol Med. 2005 Dec;140(6):733-5 [16848239.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1196-205 [16763815.001]
  • (PMID = 20402623.001).
  • [ISSN] 2162-660X
  • [Journal-full-title] Critical reviews in therapeutic drug carrier systems
  • [ISO-abbreviation] Crit Rev Ther Drug Carrier Syst
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA BC010652-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Lipids; 0 / Liposomes; 0 / Pharmaceutical Preparations; 9007-49-2 / DNA
  • [Number-of-references] 300
  • [Other-IDs] NLM/ NIHMS202285; NLM/ PMC2885142
  •  go-up   go-down


39. Davies CL, Chinn R, Nelson M, Rasanesan M, Gazzard B, Powles T, Bower M, Stebbing J: Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan. AJNR Am J Neuroradiol; 2007 Nov-Dec;28(10):1988-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan.
  • BACKGROUND AND PURPOSE: AIDS-related systemic non-Hodgkin lymphoma (ARL) remains a significant cause of morbidity and mortality in patients infected with the human immunodeficiency virus (HIV-1), and leptomeningeal disease in this setting has a dismal prognosis.
  • We investigated the utility of brain CT in determining the outcome of leptomeningeal disease, despite MR imaging being the gold standard.
  • MATERIALS AND METHODS: From a cohort of 9621 HIV-1-seropositive individuals, we identified those diagnosed with ARL in the highly active antiretroviral therapy (HAART) era who had both a lumbar puncture and central nervous system imaging using a CT brain scan at the time of initial diagnosis, and we compared survival parameters between those with and without leptomeningeal disease.
  • RESULTS: In a cohort of 82 individuals with ARL treated in the era of HAART, we found that the survival of individuals with leptomeningeal disease defined as the presence of cells in the CSF was worse compared with that of other patients (P = .0026).
  • [MeSH-major] Brain / radiography. HIV-1. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / radiography. Meningeal Neoplasms / radiography. Tomography, X-Ray Computed


40. Miralles P, Berenguer J, Ribera Santasusana JM, Calvo F, Díaz Mediavilla J, Díez-Martín JL, Gomez Codina J, López Aldeguer J, Rubio R, Santos J, Valencia E: [GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients]. Med Clin (Barc); 2008 Mar 8;130(8):300-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients].
  • [Transliterated title] Recomendaciones de GESIDA/PETHEMA sobre el diagnóstico y el tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / therapy. Practice Guidelines as Topic
  • [MeSH-minor] AIDS-Related Opportunistic Infections / prevention & control. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358123.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 89
  •  go-up   go-down


41. Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T, Horie R: Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect; 2008 Jun;10(7):748-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) causes EBV-associated lymphoproliferative diseases in patients with profound immune suppression.
  • Most of these diseases are life-threatening and the prognosis of AIDS-associated lymphomas is extremely unfavorable.
  • We investigated the possibility of nuclear factor kappa B (NF-kappaB) inhibition by dehydroxymethylepoxyquinomicin (DHMEQ) for the treatment and prevention of EBV-associated lymphoproliferative diseases.
  • These results suggest that NF-kappaB is a molecular target for the treatment and prevention of EBV-associated lymphoproliferative diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538617.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / Immunologic Factors; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin
  •  go-up   go-down


42. Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES: Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther; 2009 Nov;8(22):2136-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.
  • Primary effusion lymphoma (PEL) is a common cancer in AIDS patients closely associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • Previously, we showed that KSHV latency associated nuclear antigen (LANA) stabilizes intracellular activated Notch1 (ICN) involved in maintenance of the malignant phenotype of KSHV infected PEL cells in vitro.
  • In contrast, GSI had no effect on mice harboring BJAB cells, a KSHV negative Burkitt's lymphoma cell line where ICN levels were negligible.
  • Our study provides further evidence to suggest that targeted downregulation of abnormal Notch signaling has therapeutic potential for KSHV related primary effusion lymphomas.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Dipeptides / therapeutic use. Herpesviridae Infections. Herpesvirus 8, Human / pathogenicity. Lymphoma, Primary Effusion / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, Notch1 / antagonists & inhibitors. Tumor Virus Infections
  • [MeSH-minor] Animals. Antigens, Viral / physiology. Apoptosis. Burkitt Lymphoma / pathology. Cell Line, Tumor / transplantation. Herpesvirus 4, Human / isolation & purification. Herpesvirus 4, Human / pathogenicity. Mice. Mice, Inbred NOD. Mice, SCID. Necrosis. Nuclear Proteins / physiology. Random Allocation. Signal Transduction / drug effects. Specific Pathogen-Free Organisms. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(22):2144-6 [20068386.001]
  • (PMID = 19783901.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / PHS HHS / / A1067037; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / CA108461; United States / NIDCR NIH HHS / DE / DE017338
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Dipeptides; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Neoplasm Proteins; 0 / Notch1 protein, mouse; 0 / Nuclear Proteins; 0 / Receptor, Notch1; 0 / latency-associated nuclear antigen; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


43. Pantanowitz L, Castillo J, Freeman JK, Dezube BJ: Images in HIV/AIDS. Fatal HIV-associated anaplastic large-cell lymphoma. AIDS Read; 2009 Jan;19(1):19-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in HIV/AIDS. Fatal HIV-associated anaplastic large-cell lymphoma.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / mortality. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Anaplastic / etiology. Lymphoma, Large-Cell, Anaplastic / pathology


44. Bonnet F, Balestre E, Thiébaut R, Morlat P, Pellegrin JL, Neau D, Dabis F, Groupe d'Epidemiologie Clinique du SIDA en Aquitaine: Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin Infect Dis; 2006 Feb 1;42(3):411-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
  • BACKGROUND: High grade non-Hodgkin lymphoma (NHL) remains the most common Acquired Immune Deficiency Syndrome (AIDS)-associated neoplasia and an important cause of mortality in people living with human immunodeficiency virus (HIV) infection in industrialized countries in the era of highly active antiretroviral therapy (HAART).
  • METHOD: A case-control study was implemented in a large cohort of HIV-infected patients.
  • RESULTS: Variables associated with a decreased risk of NHL were the use of HAART during follow-up for at least 6 months (odds ratio [OR], 0.46; 95% confidence interval [CI], 0.21-0.98), receipt of a diagnosis of AIDS before the censoring date (OR, 0.37; 95% CI, 0.18-0.76), and undetectable level of HIV RNA during follow-up (OR, 0.34; 95% CI, 0.15-0.77).
  • The use of antiherpetic drug for at least 6 months was associated with a nonsignificant decreased risk of NHL (OR, 0.40; 95% CI, 0.11-1.44; P=.16).
  • In multivariate analysis, variables significantly associated with a decreased risk of NHL were the use of HAART for at least 6 months during follow-up (OR, 0.37; 95% CI, 0.16-0.87) and receipt of an AIDS-related diagnosis before the censoring date (OR, 0.44; 95% CI, 0.21-0.93).
  • Age, transmission group, hepatitis B and C coinfections, CD4(+) and CD8(+) cell count nadir, and previous history of herpes virus infection were not associated with an increased risk for NHL.
  • CONCLUSION: The use of HAART for at least 6 months was associated with a decreased risk of NHL, whereas uncontrolled HIV RNA load may be associated with an increased risk.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Antiviral Agents / therapeutic use. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Case-Control Studies. Cohort Studies. Female. France. HIV-1 / metabolism. Humans. Male. Middle Aged. Multivariate Analysis. RNA, Viral / blood. Risk Factors. Sarcoma, Kaposi / etiology


45. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch CJ, Vilchez RA, McGregor D, Jorgensen JL: Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol; 2005 Jun;18(6):806-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.
  • Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma.
  • However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma.
  • To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS.
  • All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype.
  • PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas.
  • Three markers that are often aberrantly expressed in cases of plasma cell myelomas, CD56, CD4 and CD10, were positive in 5/9, 2/5, and 6/9 plasmablastic lymphomas, and in 3/7, 1/5, and 2/7 plasmablastic plasma cell myelomas.
  • The only significant difference between plasmablastic lymphoma and plasma cell myeloma was the presence of EBV-encoded RNA, which was positive in all plasmablastic lymphoma cases tested and negative in all plasma cell myelomas.
  • In conclusion, most cases of AIDS-related plasmablastic lymphoma have an immunophenotype and tumor suppressor gene expression profile virtually identical to plasmablastic plasma cell myeloma, and unlike diffuse large B-cell lymphoma.
  • These results do not support the suggestion in the WHO classification that plasmablastic lymphoma is a variant of diffuse large B-cell lymphoma.
  • [MeSH-major] Immunophenotyping. Lymphoma / pathology. Multiple Myeloma / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. DNA, Viral / genetics. DNA-Binding Proteins / analysis. Epstein-Barr Virus Infections / immunology. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / genetics. Herpesvirus 8, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Ki-67 Antigen / analysis. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Male. Middle Aged. Polymerase Chain Reaction. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mod Pathol. 2005 Jun;18(6):873. Medeiros, Leonard J [corrected to Medeiros, L Jeffrey]
  • (PMID = 15578069.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


46. Oppenheim S: Prognosis in HIV-associated malignancies #214. J Palliat Med; 2009 Sep;12(9):835-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis in HIV-associated malignancies #214.
  • [MeSH-major] HIV Infections / complications. Neoplasms / etiology
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related. Prognosis. Risk Factors. Sarcoma, Kaposi / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719374.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Kumar GG, Mahadevan A, Guruprasad AS, Kovoor JM, Satishchandra P, Nath A, Ranga U, Shankar SK: Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature. J Magn Reson Imaging; 2010 Jun;31(6):1469-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cerebral toxoplasmosis remains one of the most common focal brain lesions in patients with acquired immune deficiency syndrome (AIDS).
  • Diagnosis is a challenge because on cranial imaging it closely mimics central nervous system lymphoma, primary and metastatic central nervous system (CNS) tumors, or other intracranial infections like tuberculoma or abscesses.
  • Herein we correlate the underlying histopathology to the MR feature of eccentric target sign in a patient with autopsy-proven HIV/AIDS-related cerebral toxoplasmosis.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Med Res. 2000 Jan;111:14-23 [10793489.001]
  • [Cites] Ann Neurol. 1986 Mar;19(3):224-38 [3963767.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1653-63 [7502971.001]
  • [Cites] Semin Roentgenol. 2007 Apr;42(2):62-91 [17394921.001]
  • [Cites] Neuroimaging Clin N Am. 1997 May;7(2):171-86 [9113684.001]
  • [Cites] Indian J Med Res. 2005 Apr;121(4):468-88 [15817957.001]
  • [Cites] Clin Radiol. 2006 May;61(5):393-401 [16679111.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):417-22 [8626904.001]
  • (PMID = 20512900.001).
  • [ISSN] 1522-2586
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS055628-01A2; United States / NINDS NIH HHS / NS / R01 NS055628; United States / NINDS NIH HHS / NS / 1R01NS055628-01A2; United States / NINDS NIH HHS / NS / R01 NS055628-01A2
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS218257; NLM/ PMC2908244
  •  go-up   go-down


48. Collins JA, Hernández AV, Hidalgo JA, Villena J, Sumire J, Delgado V, Salazar R, Almenara Hospital AIDS Working Group: High proportion of T-cell systemic non-Hodgkin lymphoma in HIV-infected patients in Lima, Peru. J Acquir Immune Defic Syndr; 2005 Dec 15;40(5):558-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High proportion of T-cell systemic non-Hodgkin lymphoma in HIV-infected patients in Lima, Peru.
  • OBJECTIVE: Few reports have described the clinical and pathologic characteristics of HIV-related systemic non-Hodgkin lymphoma (sNHL) in developing countries.
  • We aimed to determine these characteristics from a national HIV reference center in Peru and to evaluate factors associated with survival.
  • METHODS: A retrospective/prospective study of patients with HIV-related sNHL from the Guillermo Almenara General Hospital in Lima, Peru between 1993 and 2004.
  • Clinical characteristics at diagnosis included age, gender, risk behavior, previous AIDS diagnosis, opportunistic diseases, previous highly active antiretroviral therapy, Karnofsky score, origin, clinical stage and B-cell symptoms of sNHL, and CD4 cell count.
  • Ten patients (30%) had a prior history of AIDS, 14 (42%) had a Karnofsky score of <or=70, and 18 (56%) had clinical stage IV sNHL.
  • Although there were no significant differences in clinical characteristics between phenotypes, patients with T-cell sNHL had less aggressive disease and a better survival rate.
  • CONCLUSIONS: A high proportion of T-cell sNHL cases was found at an HIV reference center in Peru.
  • Clinical characteristics were similar between B-cell and T-cell lymphoma patients.
  • T-cell lymphoma was less aggressive, and patients with T-cell lymphoma had a better survival rate than those with B-cell lymphoma.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, T-Cell / epidemiology


49. Valencia ME: AIDS-related lymphomas--potentially curable in the HAART era. AIDS Rev; 2006 Apr-Jun;8(2):108-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas--potentially curable in the HAART era.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Female. Hodgkin Disease / drug therapy. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Prognosis. Treatment Outcome


50. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ, HIV/AIDS Cancer Match Study: Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS; 2006 Aug 1;20(12):1645-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in cancer risk among people with AIDS in the United States 1980-2002.
  • BACKGROUND: People with AIDS have heightened cancer risk from immunosuppression.
  • HAART has been available since 1996 and has reduced AIDS-related mortality, but there are few large-scale studies on cancer trends.
  • METHODS: AIDS and cancer registries in 11 US regions (1980-2002) were used to identify cancers in 375 933 people with AIDS.
  • Cancer risk relative to the general population was measured using the standardized incidence ratio (SIR), focusing on the 2 years after AIDS onset for those with AIDS in 1990-1995 and 1996-2002 (HAART era).
  • RESULTS: Between 1990-1995 and 1996-2002, risk declined for the two major AIDS-defining cancers: Kaposi sarcoma [(KS) n = 5131; SIR, 22 100 and 3640, respectively; P < 0.0001] and non-Hodgkin lymphoma [(NHL) n = 3412; SIR, 53.2 and 22.6, respectively; P < 0.0001].
  • Among non-AIDS malignancies, lung cancer was most common, but risk declined between 1990-1995 and 1996-2002 (n = 344; SIR, 3.3 and 2.6, respectively; P = 0.02).
  • Risk of Hodgkin lymphoma increased substantially over the 1990-2002 period (n = 149; SIR, 8.1 and 13.6, respectively; P = 0.003).
  • CONCLUSIONS: Dramatic declines in KS and NHL were temporally related to improving therapies, especially introduction of HAART, but those with AIDS remain at marked risk.
  • Among non-AIDS-related cancers, a recent increase in Hodgkin lymphoma was observed.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antiretroviral Therapy, Highly Active / adverse effects. Female. Hodgkin Disease / complications. Hodgkin Disease / epidemiology. Hodgkin Disease / immunology. Humans. Incidence. Kidney Neoplasms / complications. Kidney Neoplasms / epidemiology. Kidney Neoplasms / immunology. Lung Neoplasms / complications. Lung Neoplasms / epidemiology. Lung Neoplasms / immunology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged. Risk Factors. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / immunology. Sex Distribution. United States / epidemiology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / immunology


51. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M, CASCADE Collaboration: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS; 2006 Mar 21;20(5):741-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.
  • INTRODUCTION: Although HAART has led to a reduction in overall mortality among HIV-infected individuals, its impact on death from specific causes is unknown.
  • METHODS: Twenty-two cohorts of HIV-infected individuals with known dates of seroconversion are pooled in the CASCADE collaboration.
  • Causes of death (COD) were categorized into three AIDS-related and seven non-AIDS-related causes.
  • RESULTS: A total of 1938 of 7680 HIV-seroconverters died.
  • Pre-HAART, AIDS opportunistic infections (OI) was the most common COD, followed by unknown and HIV/AIDS-unspecified.
  • In the HAART era, the cumulative incidence for all AIDS-related COD decreased, OI remaining the most important.
  • The cumulative risk of death from AIDS-related malignancies, OI and non-AIDS-related malignancies decreased significantly among homosexual men (MSM), whereas the risk of dying from (un)-intentional death increased significantly among injecting drug users (IDU).
  • A non-significant increase in hepatitis/liver-related death was seen in MSM, IDU and haemophiliacs.
  • OI remain the most common COD in the HAART era, suggesting that AIDS-related events will continue to be important in the future.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Cause of Death. HIV Infections / drug therapy. HIV Infections / mortality. HIV-1
  • [MeSH-minor] AIDS-Related Opportunistic Infections / mortality. Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cohort Studies. Disease Progression. Female. Follow-Up Studies. HIV Seropositivity. Hepatitis / mortality. Hepatitis / virology. Humans. Incidence. Lymphoma, AIDS-Related / mortality. Lymphoma, AIDS-Related / virology. Male. Multivariate Analysis. RNA, Viral / blood. Risk. Substance Abuse, Intravenous


52. Carbone A, Gloghini A, Serraino D, Spina M: HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS; 2009 Jan;4(1):3-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Hodgkin lymphoma.
  • PURPOSE OF REVIEW: The focus of this review is on the current knowledge on epidemiology, pathology and treatment of HIV-associated Hodgkin lymphoma (HIV-HL).
  • RECENT FINDINGS: Among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma was recently observed.
  • However, the relationship between HIV infection, AIDS and Hodgkin lymphoma is still unclear.
  • SUMMARY: In the highly active antiretroviral therapy era, HIV-infected people seem to be at increased risk of Hodgkin lymphoma than in first years of the epidemic.
  • In these persons with improved immunity, increased CD4+ T cells provide antiapoptotic pathways and mechanisms for immune escape by tumor cells, as occurs in classic Hodgkin lymphoma among people without AIDS.
  • Several studies have documented a significant difference in the distribution of Hodgkin lymphoma subtypes in HIV-infected persons as compared with Hodgkin lymphoma in HIV-uninfected population.
  • HIV-HL exhibits special features related to the cellular background and the abundance of the neoplastic cell population, respectively.
  • The fact that latent membrane protein 1 is expressed in virtually all HIV-HL cases suggests that Epstein-Barr virus plays an etiological role in the pathogenesis of HIV-HL.
  • Recent advances in combined therapies, which are beginning to show promise in the treatment of this HIV-associated disorder, are discussed.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19339934.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Number-of-references] 50
  •  go-up   go-down


53. Valerga M, Rodríguez-Ríos E, Schtirbu R, Marino R: [Primary non-Hodgkin lymphoma of the uterine neck in a woman with acquired immunodeficiency syndrome (AIDS)]. Enferm Infecc Microbiol Clin; 2005 Oct;23(8):509-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin lymphoma of the uterine neck in a woman with acquired immunodeficiency syndrome (AIDS)].
  • [Transliterated title] Linfoma no hodgkiniano primario de cuello uterino en una mujer con síndrome de inmunodeficiencia adquirida (sida).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / complications. Uterine Neoplasms / complications


54. Hoffmann C, Tiemann M, Schrader C, Janssen D, Wolf E, Vierbuchen M, Parwaresch R, Ernestus K, Plettenberg A, Stoehr A, Fatkenheuer G, Wyen C, Oette M, Horst HA: AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood; 2005 Sep 1;106(5):1762-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping.
  • This study was undertaken to analyze the differentiation profiles assessed by immunophenotyping in AIDS-related B-cell lymphoma (ARL) and their relation to the clinical course.
  • Paraffin-embedded sections of 89 ARL cases during 1989 to 2004 were stained immunohistochemically with antibodies to CD3, CD10, CD20, CD38, CD138/Syndecan-1 (Syn-1), multiple myeloma-1/interferon regulatory factor-4 (MUM1/IRF4), B-cell lymphoma protein-2 (BCL-2), BCL-6, latent membrane protein-1 (LMP-1), and Ki-67.
  • Expression of CD10 and CD20 were associated with better overall survival (OS; P = .009 and P = .04, respectively).
  • Expression of CD20 was associated with longer disease-free survival (DFS; P = .03), whereas expression of CD138/Syn-1 was associated with shorter DFS (P = .03).
  • OS and DFS were worse in patients with immunophenotypic profiles related to post-germinal center (GC) differentiation (BCL-6 and CD10 negative, MUM1/IRF4 and/or CD138/Syn-1 positive) when compared with GC differentiation (P = .01).
  • When controlled for age-adjusted International Prognostic Index (IPI), prior AIDS-defining illness (ADI), and year of ARL diagnosis, a post-GC differentiation remained significantly associated with poor OS and DFS.
  • Expression of CD10 was associated with a preserved immunocompetence, whereas CD20 was less frequent in patients developing ARL while on highly active antiretroviral therapy (P = .04).
  • In summary, lack of CD20 or CD10 expression and a post-germinal center signature are associated with a worse prognosis in ARL.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, Differentiation / biosynthesis. Immunophenotyping / methods. Lymphoma, AIDS-Related / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / biosynthesis. Antigens, CD20 / immunology. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Follow-Up Studies. Germinal Center / immunology. Humans. Immunohistochemistry. Male. Middle Aged. Neprilysin / biosynthesis. Neprilysin / immunology. Prognosis. Regression Analysis. Reproducibility of Results. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - AIDS-HIV.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905193.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, Differentiation; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


55. López-Huertas MR, Callejas S, Abia D, Mateos E, Dopazo A, Alcamí J, Coiras M: Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. Nucleic Acids Res; 2010 Jun;38(10):3287-307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon.
  • The human immunodeficiency virus type 1 (HIV-1) regulator Tat is essential for viral replication because it achieves complete elongation of viral transcripts.
  • Second, cytoskeleton-related functions as cell morphology, proliferation, chemotaxis, polarization and actin polymerization were deeply altered in Jurkat-Tat101, but not in Jurkat-Tat72.
  • Consequently, these modifications were greatly dependent on Tat second exon and they could be related to the anergy observed in HIV-1-infected T cells.
  • [MeSH-major] Cytoskeleton / ultrastructure. HIV-1. tat Gene Products, Human Immunodeficiency Virus / chemistry

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2004;32(4):1270-8 [14981150.001]
  • [Cites] Eur J Clin Invest. 2004 Jan;34(1):57-66 [14984439.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):14331-7 [14718541.001]
  • [Cites] PLoS Biol. 2004 Jan;2(1):E6 [14737186.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Mar;20(3):297-304 [15117453.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5193-202 [15122328.001]
  • [Cites] Virology. 2004 Aug 15;326(1):79-89 [15262497.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Mol Biol. 1993 Mar 5;230(1):90-110 [8450553.001]
  • [Cites] J Virol. 1993 Jul;67(7):3739-47 [8510203.001]
  • [Cites] Virology. 1993 Aug;195(2):826-30 [8337847.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7941-5 [7690138.001]
  • [Cites] J Virol. 1993 Nov;67(11):6596-604 [8411362.001]
  • [Cites] J Biol Chem. 1993 Nov 25;268(33):24940-9 [8227056.001]
  • [Cites] J Mol Biol. 1993 Dec 5;234(3):779-815 [8254673.001]
  • [Cites] J Clin Invest. 1994 Jun;93(6):2505-13 [7515393.001]
  • [Cites] Nucleic Acids Res. 1994 Oct 25;22(21):4405-13 [7971271.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):546-54 [7859743.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2026-30 [7892219.001]
  • [Cites] Ann Neurol. 1995 Mar;37(3):373-80 [7695237.001]
  • [Cites] J Virol. 1999 Mar;73(3):1956-63 [9971775.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1581-8 [10102628.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3645-53 [10207088.001]
  • [Cites] J Virol. 1999 Aug;73(8):7080-6 [10400814.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):28837-40 [10506122.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48197-204 [15331610.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:932-41 [15818415.001]
  • [Cites] Retrovirology. 2005;2:5 [15691386.001]
  • [Cites] Retrovirology. 2005;2:6 [15698475.001]
  • [Cites] New Microbiol. 2005 Apr;28(2):95-109 [16035254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16362-7 [16260749.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38376-82 [16155003.001]
  • [Cites] J Neurosci. 2006 Apr 12;26(15):4054-62 [16611822.001]
  • [Cites] Proteomics. 2006 Apr;6 Suppl 1:S63-73 [16526095.001]
  • [Cites] J Gen Virol. 2006 Jun;87(Pt 6):1603-12 [16690925.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10439-48 [17079465.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34574-91 [16935861.001]
  • [Cites] Cell. 1986 Sep 26;46(7):1053-61 [3463433.001]
  • [Cites] J Cell Biol. 1977 Nov;75(2 Pt 1):593-605 [233748.001]
  • [Cites] EMBO J. 1988 Oct;7(10):3143-7 [3181132.001]
  • [Cites] J Virol. 1989 Mar;63(3):1181-7 [2536828.001]
  • [Cites] J Virol. 1989 Dec;63(12):5501-4 [2479775.001]
  • [Cites] Science. 1989 Dec 22;246(4937):1606-8 [2556795.001]
  • [Cites] J Virol. 1991 Feb;65(2):961-7 [1898974.001]
  • [Cites] Proteins. 1991;9(3):180-90 [2006136.001]
  • [Cites] Nature. 1991 Apr 25;350(6320):709-12 [2023633.001]
  • [Cites] J Virol. 1991 Jul;65(7):3460-7 [1645777.001]
  • [Cites] J Virol. 1992 Jun;66(6):3883-7 [1583734.001]
  • [Cites] J Exp Med. 1992 Sep 1;176(3):739-50 [1512539.001]
  • [Cites] Eur J Immunol. 1992 Oct;22(10):2729-32 [1396975.001]
  • [Cites] Nucleic Acids Res. 1992 Oct 25;20(20):5465-72 [1437564.001]
  • [Cites] J Virol. 1993 Jan;67(1):277-87 [8416373.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2917-23 [8428966.001]
  • [Cites] J Immunol. 1993 Mar 15;150(6):2544-53 [8095514.001]
  • [Cites] Science. 1995 Apr 21;268(5209):429-31 [7716549.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1552-60 [7729429.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):497-500 [7539892.001]
  • [Cites] Exp Cell Res. 1995 Jul;219(1):180-96 [7628534.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;193:51-77 [7648878.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Sep;11(9):1039-48 [8554901.001]
  • [Cites] Annu Rev Immunol. 1996;14:591-617 [8717526.001]
  • [Cites] Med Hypotheses. 1995 Nov;45(5):486-90 [8748093.001]
  • [Cites] J Virol. 1996 Nov;70(11):7734-43 [8892894.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):1014-9 [8993024.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):551-60 [9031086.001]
  • [Cites] J Virol. 1997 Mar;71(3):2495-9 [9032389.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2107-15 [9036955.001]
  • [Cites] Science. 1997 Mar 7;275(5305):1481-5 [9045614.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1224-35 [9135139.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13803-9 [9153236.001]
  • [Cites] J Biol Chem. 1997 Jun 20;272(25):16010-7 [9188504.001]
  • [Cites] J Cell Biol. 1997 Sep 22;138(6):1409-23 [9298994.001]
  • [Cites] Eur J Immunol. 1997 Nov;27(11):2805-11 [9394803.001]
  • [Cites] J Exp Med. 1998 Mar 16;187(6):875-83 [9500790.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):384-9 [9514931.001]
  • [Cites] J Virol. 1998 Jul;72(7):6113-8 [9621075.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jun;57(6):563-70 [9630236.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13153-8 [9789057.001]
  • [Cites] AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1553-9 [9840288.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] J Leukoc Biol. 2008 Mar;83(3):718-27 [18070983.001]
  • [Cites] EMBO J. 2008 Jul 9;27(13):1907-18 [18566585.001]
  • [Cites] Retrovirology. 2008;5:62 [18613978.001]
  • [Cites] Mol Biol Cell. 2008 Nov;19(11):4660-74 [18716063.001]
  • [Cites] Development. 2008 Dec;135(23):3871-9 [18948417.001]
  • [Cites] J Virol. 2008 Dec;82(23):11958-63 [18922876.001]
  • [Cites] Nat Struct Mol Biol. 2008 Dec;15(12):1287-92 [19029897.001]
  • [Cites] Retrovirology. 2009;6:47 [19454010.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Oct 15;240(2):286-91 [19576918.001]
  • [Cites] J Virol. 2000 Jan;74(1):344-53 [10590123.001]
  • [Cites] Trends Pharmacol Sci. 2000 Feb;21(2):45-8 [10664605.001]
  • [Cites] Histol Histopathol. 2000 Apr;15(2):539-49 [10809375.001]
  • [Cites] J Neurochem. 2000 Jul;75(1):109-16 [10854253.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5077-86 [10866664.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):151-8 [10899902.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11466-71 [11027346.001]
  • [Cites] C R Acad Sci III. 2000 Oct;323(10):883-94 [11098404.001]
  • [Cites] Eur J Immunol. 2001 Apr;31(4):969-79 [11298321.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5402-6 [11454683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41 [11517324.001]
  • [Cites] IUBMB Life. 2001 Mar;51(3):175-81 [11547919.001]
  • [Cites] Cell. 2001 Oct 5;107(1):27-41 [11595183.001]
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 15):2787-94 [11683412.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10400-9 [11784723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10037-41 [12096189.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30551-8 [12055194.001]
  • [Cites] Protein Sci. 2002 Nov;11(11):2606-21 [12381844.001]
  • [Cites] J Cell Biol. 2002 Nov 11;159(3):441-52 [12417576.001]
  • [Cites] BMC Biochem. 2002 Jun 10;3:14 [12069692.001]
  • [Cites] EMBO J. 2002 Dec 16;21(24):6801-10 [12486001.001]
  • [Cites] Nat Med. 2003 Feb;9(2):191-7 [12539042.001]
  • [Cites] Virology. 2003 Mar 1;307(1):154-63 [12667823.001]
  • [Cites] J Leukoc Biol. 2003 May;73(5):556-63 [12714569.001]
  • [Cites] Nat Immunol. 2003 Jun;4(6):525-32 [12717432.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):44816-25 [12947089.001]
  • [Cites] J Virol. 2004 Jan;78(2):779-89 [14694110.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4541-50 [14623895.001]
  • (PMID = 20139419.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / tat Gene Products, Human Immunodeficiency Virus; 0 / tat peptide (1-72), Human immunodeficiency virus 1
  • [Other-IDs] NLM/ PMC2879518
  •  go-up   go-down


56. Gulley ML, Tang W: Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn; 2008 Jul;10(4):279-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory assays for Epstein-Barr virus-related disease.
  • Laboratory tests for EBV have improved and are increasingly used in diagnosis, prognosis, prediction, and prevention of diseases ranging from infectious mononucleosis to selected subtypes of lymphoma, sarcoma, and carcinoma.
  • Analysis of blood using EBV viral load and serology reflects disease status and risk of progression.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Diagn Lab Immunol. 2003 Jan;10(1):78-82 [12522043.001]
  • [Cites] J Mol Diagn. 2003 Feb;5(1):15-20 [12552075.001]
  • [Cites] Virology. 2003 Feb 15;306(2):236-43 [12642097.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2028-32 [12727814.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):706-9 [12740922.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4290-7 [12576337.001]
  • [Cites] Pediatr Transplant. 2007 Mar;11(2):187-95 [17300499.001]
  • [Cites] Transplantation. 2007 Feb 27;83(4):433-8 [17318076.001]
  • [Cites] Int J Infect Dis. 2007 Mar;11(2):172-8 [16931088.001]
  • [Cites] J Med Virol. 2005 Jan;75(1):54-8 [15543583.001]
  • [Cites] J Clin Microbiol. 2004 Dec;42(12):5802-10 [15583315.001]
  • [Cites] Liver Transpl. 2007 Mar;13(3):343-8 [17154402.001]
  • [Cites] Scand J Infect Dis. 2007;39(3):235-44 [17366054.001]
  • [Cites] BMC Microbiol. 2007;7:22 [17391518.001]
  • [Cites] Histopathology. 2007 Mar;50(4):498-508 [17448026.001]
  • [Cites] Am J Transplant. 2007 May;7(5):1293-9 [17425621.001]
  • [Cites] J Clin Microbiol. 2007 May;45(5):1426-32 [17376882.001]
  • [Cites] Pediatrics. 2007 May;119(5):e1212-8 [17403820.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):887-95 [17509986.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5452-5 [10554016.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):712-5 [10655372.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2351-5 [10811107.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2745-8 [10825150.001]
  • [Cites] J Virol Methods. 2007 Jul;143(1):38-44 [17368820.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jun;136(6):986-91 [17547993.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):44-53 [17555446.001]
  • [Cites] J Microbiol Immunol Infect. 2007 Jun;40(3):216-21 [17639161.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1123-31 [17468341.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1342-8 [17449194.001]
  • [Cites] J Heart Lung Transplant. 2007 Aug;26(8):839-44 [17692789.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1806-12 [17557295.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4993-5000 [17785549.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):579-84 [17875508.001]
  • [Cites] J Med Virol. 2007 Nov;79(11):1710-21 [17854043.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3310-5 [17630352.001]
  • [Cites] Clin Infect Dis. 2007 Nov 15;45(10):1305-9 [17968825.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1358-64 [17873116.001]
  • [Cites] J Virol Methods. 2008 Jan;147(1):26-36 [17870188.001]
  • [Cites] AIDS. 2007 Oct 18;21(16):2141-9 [18090040.001]
  • [Cites] Clin Infect Dis. 2008 Jan 15;46(2):313-6 [18171268.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):288-91 [12872347.001]
  • [Cites] Pediatr Transplant. 2003 Aug;7(4):305-14 [12890010.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3254-9 [12960110.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3431-4 [12960133.001]
  • [Cites] J Gen Virol. 2003 Oct;84(Pt 10):2647-59 [13679598.001]
  • [Cites] Transplantation. 2003 Sep 27;76(6):959-64 [14508361.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5245-9 [14605174.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5419-28 [14662920.001]
  • [Cites] J Infect Dis. 2003 Dec 15;188(12):1853-64 [14673764.001]
  • [Cites] Clin Microbiol Infect. 2004 Jan;10(1):5-11 [14706081.001]
  • [Cites] Clin Chem. 2004 Feb;50(2):339-45 [14684618.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):487-91 [15113855.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38(11):1629-32 [15156453.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):688-97 [15159298.001]
  • [Cites] Diagn Mol Pathol. 2004 Jun;13(2):61-8 [15167006.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Med Hypotheses. 2004;63(4):582-7 [15325000.001]
  • [Cites] J Med Virol. 2004 Dec;74(4):612-8 [15484273.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):1036-41 [15386346.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):378-85 [15507678.001]
  • [Cites] Cell. 1986 Dec 26;47(6):883-9 [3022942.001]
  • [Cites] Am J Pathol. 1989 Dec;135(6):977-87 [2556930.001]
  • [Cites] Chin Med J (Engl). 1995 Apr;108(4):300-3 [7789220.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1207-14 [7590694.001]
  • [Cites] Hum Pathol. 1996 Jan;27(1):20-7 [8543306.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):608-14 [16572427.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):478-84 [16586109.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):665-71 [16707366.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] Methods Mol Biol. 2006;326:115-37 [16780197.001]
  • [Cites] J Clin Virol. 2006 Aug;36(4):258-63 [16762591.001]
  • [Cites] J Med Virol. 2006 Sep;78(9):1204-9 [16847960.001]
  • [Cites] J Pathol. 2006 Aug;209(4):430-5 [16710842.001]
  • [Cites] Rev Med Virol. 2006 Jul-Aug;16(4):251-61 [16791843.001]
  • [Cites] Methods Mol Biol. 2006;336:111-21 [16916257.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Acta Derm Venereol. 2006;86(5):439-42 [16955191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):714-20 [17011447.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5726-32 [17020977.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2942-9 [16835376.001]
  • [Cites] J Mol Diagn. 2006 Nov;8(5):589-97 [17065428.001]
  • [Cites] Clin Transplant. 2006 Nov-Dec;20(6):689-94 [17100717.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5414-8 [17135642.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4163-9 [16902151.001]
  • [Cites] Head Neck. 2007 Feb;29(2):109-19 [17103409.001]
  • [Cites] J Infect Dis. 2000 Oct;182(4):1013-21 [10979894.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1211-6 [11283029.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):814-21 [11380475.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1856-9 [11448896.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1853-7 [11576839.001]
  • [Cites] Transplantation. 2001 Sep 27;72(6):1012-9 [11579293.001]
  • [Cites] Transplantation. 2002 Jan 15;73(1):100-4 [11792987.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):259-67 [11863222.001]
  • [Cites] Clin Transplant. 2002 Apr;16(2):107-12 [11966780.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4364-9 [12036863.001]
  • [Cites] Transplantation. 2002 May 27;73(10):1603-10 [12042647.001]
  • [Cites] Nephrol Dial Transplant. 2002;17 Suppl 4:31-3, 35-6 [12091638.001]
  • [Cites] Am J Transplant. 2001 Jul;1(2):103-8 [12099356.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2612-9 [12171892.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):3986-92 [12409363.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9 [12419787.001]
  • [Cites] J Laryngol Otol. 1996 May;110(5):496-9 [8762329.001]
  • [Cites] Microbiol Immunol. 1997;41(4):309-12 [9159404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12616-21 [9356498.001]
  • [Cites] J Virol. 1999 Feb;73(2):1555-64 [9882361.001]
  • [Cites] Ann Neurol. 1999 Feb;45(2):259-61 [9989631.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] J Exp Med. 1999 Aug 16;190(4):567-76 [10449527.001]
  • [Cites] Mol Pathol. 1999 Apr;52(2):97-103 [10474689.001]
  • [Cites] J Med Virol. 2005 Jan;75(1):59-69 [15543571.001]
  • [Cites] J Infect Dis. 2005 Jan 15;191(2):238-42 [15609234.001]
  • [Cites] J Infect Dis. 2005 Feb 15;191(4):531-9 [15655776.001]
  • [Cites] J Infect Dis. 2005 Mar 15;191(6):985-9 [15717276.001]
  • [Cites] Clin Chem. 2005 Apr;51(4):781-4 [15708950.001]
  • [Cites] J Clin Microbiol. 2005 May;43(5):2053-7 [15872221.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] Am J Transplant. 2005 Sep;5(9):2222-8 [16095501.001]
  • [Cites] Am J Hematol. 2005 Sep;80(1):64-9 [16138335.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):780-4 [16106400.001]
  • [Cites] Hematol Oncol. 2005 Sep-Dec;23(3-4):127-32 [16342298.001]
  • [Cites] J Infect Dis. 2006 Jan 15;193(2):287-97 [16362894.001]
  • [Cites] Mol Diagn. 2005;9(4):195-200 [16392898.001]
  • [Cites] Acta Med Okayama. 2005 Dec;59(6):239-46 [16418766.001]
  • [Cites] Clin Microbiol Rev. 2006 Jan;19(1):165-256 [16418529.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):e21-5 [16421782.001]
  • [Cites] Am J Transplant. 2006 Feb;6(2):262-74 [16426310.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):460-4 [16428487.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1603-8 [16217752.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] Cancer Lett. 2006 Feb 28;233(2):247-54 [15907367.001]
  • [Cites] J Clin Microbiol. 2008 Jan;46(1):157-63 [17989187.001]
  • [Cites] J Heart Lung Transplant. 2008 Jan;27(1):7-10 [18187080.001]
  • [Cites] J Heart Lung Transplant. 2008 Jan;27(1):100-5 [18187094.001]
  • [Cites] J Mol Diagn. 2008 Jan;10(1):78-84 [18165270.001]
  • [Cites] Am J Transplant. 2008 Feb;8(2):442-5 [18211510.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1334-43 [17942757.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1420-7 [17991806.001]
  • [Cites] J Virol Methods. 2008 Mar;148(1-2):300-2 [18215427.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1436-42 [18316607.001]
  • [Cites] Leukemia. 2008 Mar;22(3):620-7 [18079737.001]
  • [Cites] Trends Immunol. 2008 Apr;29(4):195-201 [18328785.001]
  • [Cites] Transpl Immunol. 2007 Apr;17(3):203-10 [17331848.001]
  • (PMID = 18556771.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Viral Proteins
  • [Number-of-references] 146
  • [Other-IDs] NLM/ PMC2438195
  •  go-up   go-down


57. Tanaka PY, Atala MM, Pereira J, Caterino-de-Araujo A: Primary effusion lymphoma with cardiac involvement in HIV positive patient-complete response and long survival with chemotherapy and HAART. J Clin Virol; 2009 Jan;44(1):84-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary effusion lymphoma with cardiac involvement in HIV positive patient-complete response and long survival with chemotherapy and HAART.
  • Primary effusion lymphoma (PEL) is a rare type of lymphoma related to herpesvirus-8 (HHV-8), and considered an AIDS-defining condition.
  • The authors describe a case of PEL with cardiac involvement occurring in an HIV-positive patient treated with HAART and chemotherapy, who achieved complete remission and long survival.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. HIV Long-Term Survivors. Heart Neoplasms / secondary. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis


58. Seilmaier M, Hecht A, Guggemos W, Rüdisser K: [Cryptococcal meningoencephalitis related to HIV infection with resistance to fluconazole, relapse, and IRIS]. Med Klin (Munich); 2009 Jan 15;104(1):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cryptococcal meningoencephalitis related to HIV infection with resistance to fluconazole, relapse, and IRIS].
  • [Transliterated title] Kryptokokkenmeningoenzephalitis bei einem HIV-positiven Patienten mit Rezidiv bei Resistenz gegenüber Fluconazol und IRIS.
  • HISTORY AND CLINICAL FINDINGS: A 24-year-old HIV-positive patient was admitted to hospital on account of increasing headache.
  • There was no hint of an opportunistic infection nor of a lymphoma.
  • CONCLUSION: Cryptococcal meningoencephalitis is an opportunistic infection in AIDS.
  • As in other HIV associated infections, an IRIS has to be taken into account.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Antifungal Agents / therapeutic use. Drug Resistance, Fungal. Fluconazole / therapeutic use. HIV Seropositivity / drug therapy. Meningitis, Cryptococcal / drug therapy. Pyrimidines / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Cryptococcus neoformans / drug effects. Drug Therapy, Combination. Humans. Male. Recurrence. Voriconazole

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142596.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 8VZV102JFY / Fluconazole; JFU09I87TR / Voriconazole
  •  go-up   go-down


59. Sharma A, Bajpai J, Raina V, Mohanti BK: HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center. Indian J Cancer; 2010 Jan-Mar;47(1):35-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
  • AIMS: To analyze clinical features and survival in HIV-associated non-Hodgkin lymphoma (NHL) cases registered at Dr BRA Institute Rotary Cancer Hospital of AIIMS, New Delhi.
  • MATERIALS AND METHODS: We have retrospectively reviewed records of NHL patients registered, from January 2003 to July 2007 to analyze HIV-associated NHL.
  • RESULTS: Seven cases of HIV-associated NHL cases were identified.
  • Three cases had nodal lymphoma and four had extra nodal lymphoma.
  • No primary CNS (PCNSL) lymphoma was seen.
  • HIV infection was diagnosed as part of NHL work-up in five patients.
  • RESPONSE: One patient achieved complete response (CR) and continues to be disease free, with 4.5 years of follow-up.
  • Three cases achieved partial response (PR) and 2 had progressive disease (PD).
  • [MeSH-major] HIV Infections / complications. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology


60. Jablonowski H: [Diagnostics of the HIV infection]. MMW Fortschr Med; 2005 Apr 25;147 Spec No 1:5-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostics of the HIV infection].
  • [Transliterated title] Die akute HIV-Infektion wird häufig übersehen. Dran denken, und bei Verdacht nicht mit dem H1V-test zögern!
  • Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of mononucleosis with lymphadenopathy, fatigue and fever.
  • Ulcerations in atypical locations of the gastrointestinal tract could also indicate an HIV infection.
  • For cases of clear lymphopenia, an HIV infection should be definitely considered.
  • Above all, the presence of non-Hodgkin's lymphoma is characteristic of the complete clinical picture of AIDS.
  • An appropriate diagnostic test (antibody test or detection of HIV) is urgently indicated in situations that carry a high risk for HIV transmission.
  • This applies, above all, to patients whose partner is HIV positive, to patients who frequently change sex partners, to prostitutes and to intravenous drug users.
  • [MeSH-major] AIDS Serodiagnosis. HIV Infections / diagnosis
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. Diagnosis, Differential. Early Diagnosis. Germany. HIV Seroprevalence. Humans

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16385861.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Youngster I, Vaisben E, Cohen H, Nassar F: An unusual cause of pleural effusion. Age Ageing; 2006 Jan;35(1):94-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a unique clinicopathological entity associated with human herpesvirus-8 (HHV-8) infection, occurring almost exclusively in human immunodeficiency virus (HIV)-infected individuals.
  • We report a rare case of HHV-8-negative PEL in an HIV-negative elderly patient who presented with pleural effusion.
  • As opposed to the general poor outcome of this disease, our patient achieved complete remission and is still without signs of disease 11 months after the last treatment.
  • [MeSH-major] Lymphoma, AIDS-Related / complications. Pleural Effusion, Malignant / etiology
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Follow-Up Studies. HIV. Humans. Male. Prednisone / therapeutic use. Vincristine / therapeutic use

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364944.001).
  • [ISSN] 0002-0729
  • [Journal-full-title] Age and ageing
  • [ISO-abbreviation] Age Ageing
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


62. Tirado-Ramos A, Saltz J, Lechowicz MJ: HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes. Stud Health Technol Inform; 2010;159:239-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes.
  • Technological innovations such as web services and collaborative Grid platforms like caGrid can create opportunities to converge the worlds of health care and clinical research, by facilitating access and integration of HIV-related malignancy clinical and outcomes data at more sophisticated, semantic levels.
  • At the same time, large numbers of randomized clinical trial and outcomes data on AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) have been produced during the last few years.
  • This is a white paper on work in progress from Emory University's HIV/AIDS related malignancy data integrative knowledge base project (HIV-K).
  • We are working to increase the understanding of available clinical trial data and outcomes of ADM such as lymphoma, as well as nADM such as anal cancer, Hodgkin lymphoma, or liver cancer.
  • Our hypothesis is that, by creating prototypes of tools for semantics-enabled integrative knowledge bases for HIV/AIDS-related malignancy data, we will facilitate the identification of patterns and potential new overall evidence, as well as the linking of integrated data and results to registries of interest.
  • [MeSH-major] Databases, Factual. HIV-1. Lymphoma, AIDS-Related / therapy. Semantics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - How to Tell Patients .
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Dec 1;112(12):4384-99 [19029456.001]
  • [Cites] PLoS One. 2009;4(3):e4724 [19266092.001]
  • [Cites] J Clin Exp Neuropsychol. 2010 Apr;32(4):398-407 [19763997.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Stat Med. 1988 Nov;7(11):1121-37 [3201038.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Public Health. 2005;95 Suppl 1:S144-50 [16030331.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1910-6 [16766552.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):335-42 [16782210.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • (PMID = 20543443.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409-11; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NCRR NIH HHS / RR / UL1 RR025008-04; United States / NCATS NIH HHS / TR / UL1 TR000454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS315000; NLM/ PMC3157699
  •  go-up   go-down


63. Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group: HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS; 2008 Oct 18;22(16):2143-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
  • OBJECTIVE: To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency.
  • We used Poisson regression models to identify factors independently associated with deaths from ADM and nADM.
  • Analyses of factors associated with mortality due to nADM were repeated after excluding nADM known to be associated with a specific risk factor.
  • In multivariable regression analyses, a two-fold higher latest CD4 cell count was associated with a halving of the risk of ADM mortality.
  • Other predictors of an increased risk of ADM mortality were homosexual risk group, older age, a previous (non-malignancy) AIDS diagnosis and earlier calendar years.
  • CONCLUSION: The severity of immunosuppression is predictive of death from both ADM and nADM in HIV-infected populations.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutagenesis. 2005 Mar;20(2):139-46 [15784690.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2005 Sep 15;41(6):855-63 [16107986.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] AIDS. 2006 Jan 2;20(1):49-57 [16327319.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):397-406 [16983127.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):239-47 [17358029.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Blood. 2000 May 1;95(9):2860-8 [10779432.001]
  • [Cites] AIDS. 2000 May 5;14(7):771-80 [10839584.001]
  • [Cites] Lancet. 2000 Oct 21;356(9239):1423-30 [11052597.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] AIDS. 2002 Aug 16;16(12):1663-71 [12172088.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2002 Jul 26;51(29):642-5 [12186222.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):121-30 [15561752.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):407-9 [15769998.001]
  • [Cites] J Hepatol. 2005 Jun;42(6):799-805 [15973779.001]
  • (PMID = 18832878.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / 5U01AI046362-03; United States / NIAID NIH HHS / AI / U01 AI069907-02; United States / NIAID NIH HHS / AI / U01 AI046362; United States / NIAID NIH HHS / AI / 5U01AI042170-10; United States / NIAID NIH HHS / AI / U01 AI069907; United States / NIAID NIH HHS / AI / U01 AI042170
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS113887; NLM/ PMC2715844
  • [Investigator] Collins S; Loeliger E; Tressler R; Weller I; Friis-Møller N; Worm SW; Sabin CA; Sjøl A; Lundgren JD; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjaer J; de Wolf F; Zaheri S; Gras L; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Schattenkerk JK; Geerlings SE; Godfried MH; Lange JM; van Leth FC; Lowe SH; van der Meer JT; Nellen FJ; Pogány K; van der Poll T; Reiss P; Ruys TA; Sankatsing SR; van Twillert G; van der Valk M; van Vonderen MG; Vrouenraets SM; van Vugt M; Wit FW; van Eeden A; ten Veen JH; van Dam PS; Roos JC; Brinkman K; Frissen PH; Weigel HM; Mulder JW; van Gorp EC; Meenhorst PL; Mairuhu AT; Veenstra J; Danner SA; Van Agtmael MA; Claessen FA; Perenboom RM; Rijkeboer A; van Vonderen M; Richter C; van der Berg J; van Leusen R; Vriesendorp R; Jeurissen FJ; Kauffmann RH; Koger EL; Bravenboer B; ten Napel CH; Kootstra GJ; Sprenger HG; Miesen WM; Doedens R; Scholvinck EH; ten Kate RW; van Houte DP; Polee M; Kroon FP; van den Broek; van Dissel JT; Schippers EF; Schreij G; van de Geest S; Verbon A; Koopmans PP; Keuter M; Post F; van der Ven AJ; van der Ende ME; Gyssens IC; van der Feltz M; den Hollander JG; de Marie S; Nouwen JL; Rijnders BJ; de Vries TE; Juttmann JR; van de Heul C; van Kasteren ME; St Elisabeth SM; Bonten MJ; Borleffs JC; Ellerbroek PM; Hoepelman IM; Jaspers CA; Schouten I; Schurink CA; Blok WL; Tanis AA; Groeneveld PH; Salamon R; Beylot J; Dupon M; Le Bras M; Pellegrin JL; Ragnaud JM; Dabis F; Chêne G; Jacqmin-Gadda H; Thiébaut R; Lawson-Ayayi S; Lavignolle V; Balestre E; Blaizeau MJ; Decoin M; Formaggio AM; Delveaux S; Labarerre S; Uwamaliya B; Vimard E; Merchadou L; Palmer G; Touchard D; Dutoit D; Pereira F; Boulant B; Beylot J; Morlat P; Bernard N; Bonarek M; Bonnet F; Coadou B; Gelie P; Jaubert D; Nouts C; Lacoste D; Dupon M; Dutronc H; Cipriano G; Lafarie S; Chossat I; Lacut JY; Leng B; Pellegrin JL; Mercié P; Viallard JF; Faure I; Rispal P; Cipriano C; Tchamgoué S; Le Bras M; Djossou F; Malvy D; Pivetaud JP; Ragnaud JM; Chambon D; De La Taille C; Galperine T; Lafarie S; Neau D; Ochoa A; Beylot C; Doutre MS; Bezian JH; Moreau JF; Taupin JL; Conri C; Constans J; Couzigou P; Castera L; Fleury H; Lafon ME; Masquelier B; Pellegrin I; Trimoulet P; Moreau F; Mestre C; Series C; Taytard A; Law M; Glenday K; Petoumenos K; Anderson J; Cortissos P; Mijch A; Watson K; Roth N; Nicolson J; Bloch M; Agrawal S; Franic T; Baker D; Vale R; Carr A; Cooper D; Lacey M; Hesse K; Chuah J; Lester D; Fankhauser W; Mallal S; Forsdyke C; Bulgannawar S; Calvo G; Torres F; Mateu S; Domingo P; Sambeat MA; Gatell J; Del Cacho E; Cadafalch J; Fuster M; Codina C; Sirera G; Vaqué A; Clumeck N; De Wit S; Gerard M; Kabeya K; Konopnicki D; Libois A; Payen MC; Poll B; Van Laethem Y; Neaton J; Bartsch G; El-Sadr WM; Krum E; Thompson G; Wentworth D; Luskin-Hawk R; Telzak E; El-Sadr WM; Abrams DI; Cohn D; Markowitz N; Arduino R; Mushatt D; Friedland G; Perez G; Tedaldi E; Fisher E; Gordin F; Crane RL; Sampson J; Baxter J; Kirk O; Olsen CH; Mocroft A; Phillips AN; Lundgren JD; Vetter N; Karpov I; Vassilenko A; Clumeck N; De Wit S; Poll B; Colebunders R; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Benfield T; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Zilmer K; Katlama C; Viard JP; Girard PM; Saint-Marc T; Vanhems P; Pradier C; Dabis F; Dietrich M; Manegold C; van Lunzen J; Stellbrink HJ; Staszewski S; Bieckel M; Goebel FD; Fätkenheuer C; Rockstroh J; Schmidt RE; Kosmidis J; Gargalianos P; Sambatakou H; Perdios J; Panos G; Filandras A; Banhegyi D; Mulcahy F; Yust I; Burke M; Turner D; Pollack S; Hassoun J; Sthoeger Z; Maayan S; Vella S; Chiesi A; Arici C; Pristerá R; Mazzotta F; Gabbuti A; Esposito R; Bedini A; Chirianni A; Montesarchio E; Vullo V; Santopadre P; Narciso P; Antinori A; Franci P; Zaccarelli M; Lazzarin A; Castagna A; Monforte Ad; Viksna L; Chaplinskas S; Hemmer R; Staub T; Reiss P; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Prokopowicz D; Wiercinska-Drapalo A; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Antunes F; Mansinho K; Maltez F; Duiculescu D; Babes V; Streinu-Cercel A; Vinogradova E; Rakhmanova A; Jevtovic D; Mokrás M; Staneková D; González-Lahoz J; Sanchez-Conde M; García-Benayas T; Martin-Carbonero L; Soriano V; Clotet B; Jou A; Conejero J; Ruiz L; Tural C; Gatell JM; Miró JM; Zamora L; Blaxhult A; Karlsson A; Pehrson P; Ledergerber B; Weber R; Francioli P; Telenti A; Hirschel B; Soravia-Dunand V; Furrer H; Kravchenko E; Chentsova N; Fisher M; Brettle R; Barton S; Johnson AM; Mercey D; Murphy M; Johnson MA; Weber J; Scullard G; Morfeldt L; Thulin G; Sundström A; Akerlund B; Koppel K; Karlsson A; Flamholc L; Håkangård C; Monforte Ad; Ammassari A; Antinori A; Maggiolo F; Balotta C; Bonfanti P; Capobianchi M; Castagna A; Ceccherini-Silberstein F; Cozzi-Lepri A; Monforte Ad; De Luca A; Gervasoni C; Girardi E; Lo Caputo S; Murri R; Mussini C; Puoti M; Torti C; Moroni M; Carosi G; Cauda R; Chiodo F; Monforte Ad; Di Perri G; Galli M; Iardino R; Ippolito G; Lazzarin A; Mazzotta F; Panebianco R; Pastore G; Perno CF; Montroni M; Scalise G; Costantini A; Riva A; Tirelli U; Martellotta F; Pastore G; Ladisa N; Suter F; Maggiolo F; Chiodo F; Colangeli V; Fiorini C; Carosi G; Cristini G; Torti C; Minardi C; Bertelli D; Quirino T; Manconi PE; Piano P; Pizzigallo E; D'Alessandro M; Carnevale G; Zoncada A; Ghinelli F; Sighinolfi L; Leoncini F; Mazzotta F; Pozzi M; Lo Caputo S; Grisorio B; Ferrara S; Pagano G; Cassola G; Alessandrini A; Piscopo R; Soscia F; Tacconi L; Orani A; Perini P; Tommasi D; Congedo P; Chiodera F; Castelli P; Moroni M; Lazzarin A; Rizzardini G; Caggese L; Monforte Ad; Galli A; Merli S; Pastecchia C; Moioli MC; Esposito R; Mussini C; Gori A; Cagni S; Abrescia N; Chirianni A; Izzo CM; De Marco M; Viglietti R; Manzillo E; Ferrari C; Pizzaferri P; Filice G; Bruno R; Magnani G; Ursitti MA; Arlotti M; Ortolani P; Cauda R; Andreoni M; Antinori A; Antonucci G; Narciso P; Tozzi V; Vullo V; De Luca A; Zaccarelli M; Acinapura R; De Longis P; Trotta MP; Lichtner M; Carletti F; Mura MC; Mannazzu M; Caramello P; Di Perri G; Orofino GC; Sciandra M; Raise E; Ebo F; Pellizzer G; Buonfrate D; Pradier C; Fontas E; Caissotti C; Dellamonica P; Bentz L; Bernard E; De Salvador-Guillouet F; Durant J; Mondain-Miton V; Perbost I; Prouvost-Keller B; Pugliese P; Rahelinirina V; Roger PM; Vandenbos F; Battegay M; Bernasconi E; Böni J; Bucher H; Bürgisser P; Cattacin S; Cavassini M; Dubs R; Egger M; Elzi L; Erb P; Fischer M; Flepp M; Fontana A; Francioli P; Furrer HJ; Gorgievski M; Günthard H; Hirschel B; Kaiser L; Kind C; Klimkait T; Lauper U; Ledergerber B; Opravil M; Paccaud F; Pantaleo G; Perrin L; Piffaretti JC; Rickenbach M; Schmid CR; Schüpbach J; Speck R; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S
  •  go-up   go-down


64. Said JW: Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol; 2007 May;14(3):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunodeficiency-related Hodgkin lymphoma and its mimics.
  • Classic Hodgkin lymphoma (CHL) in patients with underlying immunodeficiency disorders frequently differs from that in the immune competent population in terms of its clinical behavior and pathologic features.
  • Topics under review include: (a) CHL posttransplant lymphoproliferative disorders, (b) CHL in HIV/AIDS, (c) Hodgkin variant of Richter syndrome in chronic lymphocytic leukemia in association with fludarabine therapy, (d) CHL in other immunodeficiency states including methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis and primary immune deficiencies, and (e) Hodgkin-like lymphoid proliferations including senile Epstein-Barr virus+ B-cell lymphoproliferative disorder.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Hodgkin Disease / etiology. Hodgkin Disease / immunology. Hodgkin Disease / pathology. Immunologic Deficiency Syndromes / complications. Lymphoma, AIDS-Related / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. HIV Infections / complications. Herpesvirus 4, Human. Humans. Immunocompromised Host. Organ Transplantation / adverse effects


65. Mwanda WO, Whalen C, Remick SC: Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa. East Afr Med J; 2005 Sep;82(9 Suppl):S133-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Burkitt Lymphoma / drug therapy. Epstein-Barr Virus Infections / drug therapy. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / drug therapy. Lymphoproliferative Disorders / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619688.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Grant] United States / PHS HHS / / A136219; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Kenya
  •  go-up   go-down


71. Osorio S G, Montenegro U C: [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review]. Rev Chilena Infectol; 2007 Apr;24(2):117-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review].
  • [Transliterated title] Linfomas asociados a infección por virus de inmunodeficiencia humana en un complejo hospitalario de la Región Metropolitana, Chile: 1990-2002. Reporte de 14 casos y revisión.
  • The association of HIV infection and lymphoma in patients attending at the South Health Metropolitan Reference Centre is presented.
  • RESULTS: 14 cases were detected, 10 non Hodgkin lymphoma patients (7 with high malignancy and 50% in stages III-IVB) and 4 with Hodgkin lymphoma (3 with mixed cellularity, 2 in stage IVB).
  • Ten patients were classified under stage C3 of AIDS CDC criteria, the mean CD4 count was 139 cells/mm3 and mean CV was 5,32 log.
  • Eighty six percent of patients presented with unique or multiples lymphonodes, with predominance of advanced lymphoma stage.
  • Conventional CHOP chemotherapy was the treatment for high risk and extended non Hodgkin lymphomas and for extended Hodgkin lymphomas the ABVD protocol was administered.
  • Global mortality in this series was 71%, attributable to tumor disease per se or to sepsis.
  • Four patients survived (18 to 50 months) in complete remission, 2 non Hodgkin lymphomas and 2 Hodgkin lymphomas.
  • The low incidence of lymphoma and AIDS association and the high frequency of lymphomas with localized or generalized lymphonodes in this series are remarkable.
  • [MeSH-major] Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Chile / epidemiology. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453069.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 30
  •  go-up   go-down


72. Perret D, Rousseau F, Tran V, Gascan H: Reversal of some viral IL-6 electrostatic properties compared to IL-6 contributes to a loss of alpha receptor component recruitment. Proteins; 2005 Jul 1;60(1):14-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human herpesvirus-8 (HHV-8) has been associated with classical and AIDS-related Kaposi's sarcoma (KS).
  • HHV-8 encodes viral IL-6 (vIL-6), a functional homolog of human interleukin-6, that promotes the growth of KS and of some lymphoma cells.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861391.001).
  • [ISSN] 1097-0134
  • [Journal-full-title] Proteins
  • [ISO-abbreviation] Proteins
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Receptors, Interleukin-6; 0 / Viral Proteins; 133483-10-0 / Cytokine Receptor gp130
  •  go-up   go-down


73. Abbate I, Cappiello G, Longo R, Ursitti A, Spanò A, Calcaterra S, Dianzani F, Antinori A, Capobianchi MR: Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders. Infect Genet Evol; 2005 Apr;5(3):247-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders.
  • Cell membrane protein (CMP) profile of HIV-1 from cerebrospinal fluid (CSF) and plasma of five AIDS patients with neurologic disorders was analyzed and compared with viral quasispecies composition in these body compartments.
  • To this aim, paired CSF and plasma samples from AIDS subjects with HIV-related neurological diseases (three HIV-1 encephalopaty (HIVE) and two primary CNS lymphoma (PCNSL)) underwent immobilized antibody capture (IAC) assay to determine the profile of CMP acquired by HIV-1.
  • The results indicated that CD44 and CD58 were the most represented molecules on HIV-1 from CSF, whereas CD36 was the most abundant molecule on plasma HIV-1.
  • The degree of genetic heterogeneity (both complexity and diversity) in p17 gag was significantly lower in CSF-HIV than that in plasma-HIV for three patients, higher for one patient, and not significantly different for one patient, suggesting compartmentalization for all but the latter patient.
  • When considering the pattern of CMP, the most abundant CMP observed in HIV from plasma and CSF was different in patients showing compartmentalization, while was the same in the patient without significant differences in CSF and plasma quasispecies.
  • In conclusion, the present data on CMP pattern, V3 loop aminoacidic signature and genetic heterogeneity of HIV-1 quasispecies from CSF and plasma of HIVE patients, are consistent with a compartmentalized virus replication, at least in some patients, and with a possible different source of HIV in the two body sites, even though in a context of a largely prevalent M-R5 phenotype.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Cell Compartmentation / physiology. HIV-1 / pathogenicity. Membrane Proteins / blood. Membrane Proteins / cerebrospinal fluid. Nervous System Diseases / virology
  • [MeSH-minor] AIDS Dementia Complex / blood. AIDS Dementia Complex / cerebrospinal fluid. AIDS Dementia Complex / etiology. AIDS Dementia Complex / virology. Adult. Female. Gene Products, gag / blood. Gene Products, gag / cerebrospinal fluid. Gene Products, gag / genetics. Genetic Variation. Humans. Male. Viral Proteins / blood. Viral Proteins / cerebrospinal fluid. Virus Replication


74. Bishop JA, Westra WH: Plasmablastic lymphoma involving the parotid gland. Head Neck Pathol; 2010 Jun;4(2):148-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma involving the parotid gland.
  • Plasmablastic lymphoma is a rare form of non-Hodgkin lymphoma.
  • It is strongly associated with HIV infection, although it has been recognized in immunocompetent patients.
  • Plasmablastic lymphoma has a predilection for the oral cavity.
  • We report a case of an HIV positive man who developed a rapidly enlarging parotid mass.
  • These findings were diagnostic of plasmablastic lymphoma.
  • Plasmablastic lymphoma is notoriously difficult to diagnose, particularly when it arises in unexpected sites outside of the oral cavity.
  • As an aggressive lymphoma, plasmablastic lymphoma must be considered in the differential diagnosis of a high-grade malignant neoplasm not just in the oral cavity but at non-oral sites including the parotid gland, particularly in an HIV-positive individual.
  • [MeSH-major] HIV Infections / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD38 / metabolism. Biomarkers, Tumor / metabolism. DNA, Viral / genetics. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology. Fatal Outcome. HIV / isolation & purification. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. Immunocompromised Host. In Situ Hybridization. Male. Membrane Glycoproteins / metabolism. Plasma Cells / metabolism. Plasma Cells / pathology. RNA-Binding Proteins / genetics. RNA-Binding Proteins / metabolism. Ribosomal Proteins / genetics. Ribosomal Proteins / metabolism. Syndecan-1 / metabolism

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Lancet Infect Dis. 2008 Apr;8(4):261-7 [18353267.001]
  • [Cites] Orbit. 2009;28(6):425-9 [19929677.001]
  • [Cites] Oral Dis. 2009 Jan;15(1):38-45 [18939960.001]
  • [Cites] J Oral Pathol Med. 2009 Jan;38(1):138-44 [18647219.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • (PMID = 20512642.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / Membrane Glycoproteins; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / SDC1 protein, human; 0 / Syndecan-1; 135844-68-7 / RPL22 protein, human; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  • [Other-IDs] NLM/ PMC2878619
  •  go-up   go-down


75. Carbone A, Gloghini A: AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol; 2005 Sep;130(5):662-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas: from pathogenesis to pathology.
  • Human immunodeficiency virus (HIV)-associated lymphomas include:.
  • (1) lymphomas also occurring, although sporadically, in the absence of HIV infection.
  • The vast majority of these lymphomas are high-grade B-cell lymphomas: Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) with centroblastic (CB) features and DLBCL with immunoblastic (IBL) features;.
  • (2) unusual lymphomas occurring more specifically in HIV-positive patients and include two rare entities, namely 'primary effusion lymphoma' (PEL) and 'plasmablastic lymphoma' of the oral cavity.
  • The pathological heterogeneity of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas (AIDS-NHL) reflects the heterogeneity of their associated molecular lesions.
  • In AIDS-BL, the molecular lesions involve activation of cMYC, inactivation of P53, and infection with Epstein-Barr virus (EBV).
  • AIDS-IBL infected with EBV are characterised by frequent expression of latent membrane protein 1--an EBV oncoprotein.
  • The biological heterogeneity of AIDS-NHL is highlighted by their histogenetic differences.
  • Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8)-associated lymphomas, which often develop in persons with advanced AIDS, present predominantly as PEL.
  • KSHV/HHV8 has also been recently detected in solid extracavitary-based lymphomas.
  • The KSHV/HHV8-associated solid lymphomas are (1) unusual lymphomas that occur more specifically in HIV-positive patients;.
  • (2) extracavitary and arise in nodal and/or extranodal sites; and (3) histologically, they usually display a PEL-like morphology and plasma cell-related phenotype.
  • [MeSH-major] HIV-1. Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin. Sarcoma, Kaposi


76. Huppmann AR, Orenstein JM: Opportunistic disorders of the gastrointestinal tract in the age of highly active antiretroviral therapy. Hum Pathol; 2010 Dec;41(12):1777-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the 1996 advent of highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS, the incidence of most opportunistic disorders in the developed world has dramatically declined but definitely has not disappeared.
  • The number of new yearly HIV infections (about 55,000) and the total number of US infections (more than 1.1 million) remain very significant.
  • Cases of adenovirus, bacterial colitis, Kaposi sarcoma, and lymphoma were still diagnosed.
  • Thus, where HIV/AIDS is common, it is important to be able to diagnose these GI processes.
  • In addition to presenting post-HAART incidences, diagnostic features and aids are described for selected entities.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / etiology. Acquired Immunodeficiency Syndrome / epidemiology. Antiretroviral Therapy, Highly Active / adverse effects. Gastrointestinal Diseases / epidemiology


77. Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales N, Webb A, AIDS Malignancy Subcommittee: British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med; 2008 Jul;9(6):336-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] British HIV Association guidelines for HIV-associated malignancies 2008.
  • [MeSH-major] HIV Infections / complications. HIV-1. Lymphoma, AIDS-Related / therapy. Sarcoma, Kaposi / therapy. Uterine Cervical Neoplasms / therapy


78. Abali H, Abali G, Aksoy S: Which one is better: AIDS related or HIV associated? J Clin Oncol; 2007 Feb 20;25(6):e6
PDF icon [Fulltext service] Get downloadable